PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
1448532566	CYP2D6 poor metabolizers	PMID:16160620	CYP2D6	CYP2D6 poor metabolizers are not associated with increased risk of tardive dyskinesia when treated with risperidone.	no	> 0.05	516		Unknown	Toxicity	false	compared to none poor metabolizer.	risperidone
613979290	rs1800497	PMID:18855532	ANKK1	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	yes	= 0.0239	120		East Asian	Efficacy	false		risperidone
769173468	rs4436578	PMID:20375926	DRD2	Genotype CC is associated with increased risk of body weight gain when treated with clozapine, olanzapine or risperidone in people with Schizophrenia.	yes	= 0.001	460		East Asian	Toxicity	false	Patients were treated with one of the three drugs: clozapine(239), olanzapine (70),risperidone(170).  Treatment was for  avg of 48.2 +/- 27.8 months.	clozapine; olanzapine; risperidone
1183629449	rs1800497	PMID:23859574	ANKK1	Genotype AA is associated with increased risk of Headache when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to genotype GG.	yes	= 0.035	161		European	Toxicity	false	A higher frequency of individuals with headache were found to have the DRD2 A1/A1 (30%) genotype vs A2/A2 (9%). Those with the A1/A2 genotype were in between (20%). Here allele A is used to represent A1 which is less frequent in Caucasian populations and G to represent A2 which is the major allele in Caucasians.  P value <0.05 for Chi-Squared analysis for this association. Statistics given below are for multivariate analysis for factors contributing to headache.	olanzapine; quetiapine; risperidone
1449181797	rs518147	PMID:29441581	HTR2C	Genotype CC is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders or Schizophrenia as compared to genotypes CG + GG.	yes	= 0.048	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1450928254	rs3813928	PMCID:PMC5538123	HTR2C	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	no	= 1	288		East Asian	Efficacy	false		risperidone
1450928241	rs3787429	PMCID:PMC5538123	HRH3	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	no	= 1	288		East Asian	Efficacy	false		risperidone
1183621249	rs6265	PMID:16633140	BDNF	Genotype TT is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotype CC.	yes	= 0.02	123		East Asian	Toxicity	false	This SNP was presented as BDNF 66-Val/Met. Patients homozygous for the Met allele showed less weight gain during treatment with risperidone as compared to patients homozygous for the Val allele. Heterozygotes showed a non-significant trend (P=.06) towards an intermediate level of weight gain due to risperidone treatment.	risperidone
1183615619	CYP2D6*1; CYP2D6*4	PMID:24026091	CYP2D6	CYP2D6 *4/*4 is associated with increased response to risperidone in people with Schizophrenia as compared to CYP2D6 *1/*1.	yes	= 0.049	75		Unknown	Efficacy	false	"The association showed a trend toward significance for CYP2D6 PM (all *4/*4)
and PANSS-T (Positive and Negative Syndrome Scale-negative) improvement after Bonferroni. When noncategorized (as responder/nonresponder), CYP2D6 PMs showed a statistically significant clinical improvement in PANSS-T compared with
extensive metabolizers p=0.001)."	risperidone
1449753190	rs3786362	PMID:29955115	TYMS	Allele A is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to allele G.	yes	= 0.105	33	51	Unknown	Toxicity	true		risperidone
1447680089	rs10848635	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.32	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1450928233	rs3803300	PMCID:PMC5538123	AKT1	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1449181811	rs12836771	PMID:29441581	HTR2C; MIR1264; MIR1912	Genotype GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AA + AG.	yes	= 0.042	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1450815085	rs813676	PMCID:PMC3922978	TJP1	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	yes	= 4.91E-07	159		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of T alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs711355 and rs785423.	risperidone
1448999496	CYP2D6 ultrarapid metabolizer phenotype	PMID:19997080	CYP2D6	CYP2D6 ultra-metabolizer phenotype is associated with decreased severity of Weight gain when treated with risperidone in children with Autistic Disorder as compared to CYP2D6 normal metabolizer phenotype.	yes	= 0.002	45		"Multiple groups, Portugal, 44 ""Caucasian"" 1 ""African"""	Toxicity	true	Ultra-rapid metabolizers phenotype was associated with a 4.8 and 5.8% lower increase in BMI and waist circumference when compared with the reference extensive metabolizers phenotype. The poor metabolizers phenotype was also associated with a 4% lower increase in waist circumference.	risperidone
1450932846	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	PMID:30661084	CYP2D6	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.	yes	= 0.04	257		Multiple groups, White Hispanic, White non-Hispanic, African American, Asian/Pacific Islander, Native American or 'Unknown' ethnicities	Toxicity	true		risperidone
982025872	rs4680	PMID:18579277		Allele G is not associated with increased risk of Hyperprolactinemia when treated with risperidone in people with Schizophrenia as compared to allele A.	no	= 0.196	174		East Asian	Toxicity	false		risperidone
1450815073	rs711355	PMCID:PMC3922978	TJP1	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	yes	= 2.25E-07	159		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of T alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs785423 and rs813676.	risperidone
1448530511	CYP2D6*1; CYP2D6*2; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*41	PMID:26944100	CYP2D6	CYP2D6 *10/*10 + *10/*41 + *1/*4 + *1/*5 are not associated with metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.	no	> 0.05	42		East Asian	Metabolism/PK	true	Genotyped with Luminex xTAG CYP2D6 Kit v3, which can identify *1, *2, *35,*9, *10, *17, *29, *41, *3, * 4, *5, *6, *7, *8, *11, *15, and duplications. The plasma concentration of risperidone in subjects with AS=1 (n=34) (1.5 ng/ml) was not significantly higher than AS=2 (n=8) (0.13 ng/ml) phenotype. The plasma concentration of risperidone/9-hydroxyrisperidone ratio in subjects with AS=1 (0.18) phenotype was not significantly higher than AS=2 (0.02).	risperidone
1447680083	rs758723	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.40	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1450928225	rs2494732	PMCID:PMC5538123	AKT1	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	no	= 1	288		East Asian	Efficacy	false		risperidone
1449181819	rs7799039	PMID:29441581	LEP	Genotype AA is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AG + GG.	no	= 0.321	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1450815079	rs785423	PMCID:PMC3922978	TJP1	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	yes	= 4.86E-07	159		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of A alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs711355 and rs813676.	risperidone
1043818007	rs1800497	PMID:23851570	ANKK1	Genotypes AA + AG are not associated with increased risk of Hyperprolactinemia when treated with risperidone in children as compared to genotype GG.	no	= 0.12	47		European	Toxicity	true	Association with higher susceptibility to risperidone-induced hyperprolactinemia. Study participants were boys with autism spectrum disorders and/or disruptive behavior disorders, chronically treated with an antipsychotic drug.	risperidone
1184136884	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMCID:PMC3619141	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with decreased likelihood of Sexual adverse events when treated with risperidone in people with Schizophrenia.	no	= 0.015	111		European	Toxicity	false	Authors state is non-significant trend. (Trend is reported for SLC6A4 L/S). Genotyping is done with the PHARMA Chip genotyping array.	risperidone
1448999549	rs6311	PMID:19997080	HTR2A	Genotype CC is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to genotypes CT + TT.	yes	= 0.018	45		"Multiple groups, Portugal, 44 ""Caucasian"" 1 ""African"""	Toxicity	true	as measured by a higher prolactin increase. Alleles complemented to plus chromosomal strand.	risperidone
1450928217	rs1805054	PMCID:PMC5538123	HTR6	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	no	= 1	288		Unknown	Efficacy	false		risperidone
1449753164	rs1976391	PMID:29955115	UGT1A1	Genotype AG is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype AA.	yes	= 0.014	33	51	Unknown	Toxicity	true	This variant was identified in the paper by its previous rsID number: rs111741722. This variant was in complete linkage disequilibrium with rs887829 and rs10929302.	risperidone
827814256	rs6280	PMCID:PMC3619141	DRD3	Allele C is associated with decreased likelihood of extrapyrimidal side effects (EPS) when treated with risperidone in people with Schizophrenia as compared to allele T.	no	= 0.015	111		European	Toxicity	false	Authors state is non-significant trend. (Trend is reported for DRD3 9Gly)	risperidone
1183491245	rs7732173	PMCID:PMC3845218	SV2C	Genotype AA is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AG + GG.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score. In significant LD (r2 > 0.95) with rs10514062 and rs2358531.	risperidone
827814269	rs6280	PMCID:PMC3619141	DRD3	Allele C is associated with increased likelihood of Sleep Disorders when treated with risperidone in people with Schizophrenia as compared to allele T.	no	= 0.05	111		European	Toxicity	false	Authors state is non-significant trend. (Trend is reported for DRD3 9Gly)	risperidone
1449753155	rs10929302	PMID:29955115	UGT1A1	Genotype AG is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype GG.	yes	= 0.014	33	51	Unknown	Toxicity	true	This SNP is also known as UGT1A1*93. This variant was in complete linkage disequilibrium with rs887829 and rs1976391.	risperidone
1450928209	rs1801133	PMCID:PMC5538123	MTHFR	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1448999542	rs6265	PMID:19997080	BDNF	Genotypes CT + TT is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to genotype CC.	yes	= 0.016	45		"Multiple groups, Portugal, 44 ""Caucasian"" 1 ""African"""	Toxicity	true	as measured by a higher prolactin increase. Alleles complemented to plus chromosomal strand.	risperidone
1183491258	rs1995380	PMCID:PMC3845218	SV2C	Genotype GG is not associated with response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	risperidone
1184136868	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:23859574	SLC6A4	SLC6A4 HTTLPR long form (L allele) is associated with increased risk of Dizziness when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	yes	= 0.015	206		European	Toxicity	false	The long allele was associated with increased likelihood of dizziness compared to patients with the short/short genotype. P value <0.05 for Chi-Squared analysis for this association. Statistics given below are for multivariate analysis for factors contributing to headache. The article used the SLC6A4 rs4795541 [5HTTLPR L/S] for identification. Historically a long insertion/deletion was submitted under this SNP. Currently, the rsnumber does not support a long insertion/deletion on dbSNP.	olanzapine; quetiapine; risperidone
1448999533	rs9659997	PMID:19997080	HTR6	Genotypes CC + CT is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to genotype TT.	yes	= 9.534E-05	45		"Multiple groups, Portugal, 44 ""Caucasian"" 1 ""African"""	Toxicity	true	as measured by a higher prolactin increase.	risperidone
1448998508	rs3813929	PMID:20195292	HTR2C	Genotype TT is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotypes CC + CT.	no	= 0.002	101		European	Toxicity	false	but there were significant increases in waist circumference, fasting blood glucose, and triglycerides which are features of metabolic syndrome. NOTE: this is x-linked gene and authors chose to only investigate in women.	olanzapine; risperidone
1449753176	rs2276299	PMID:29955115	SLC22A8	Allele A is not associated with risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to allele T.	no	= 0.117	33	51	Unknown	Toxicity	true		risperidone
1450928201	rs1800497	PMCID:PMC5538123	DRD2	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1183621311	CYP2D6*1; CYP2D6*10	PMID:16633140	CYP2D6	CYP2D6 *10 is associated with increased severity of weight gain due to risperidone in people with Schizophrenia as compared to CYP2D6 *1.	yes	= 0.04	123		East Asian	Toxicity	false	This was presented as CYP2D6 188-C/T. Patients with the wildtype *1/*1 genotype showed less weight gain during treatment with risperidone as compared to patients carrying the *10 allele.	risperidone
655388451	rs1414334	PMID:20680028	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	yes	= 0.015	186		European	Toxicity	false	Note: this is an x-linked gene on plus strand. Male subjects have only one copy of the allele (C or G) whereas female subjects can be CC, CG or GG.	antipsychotics; aripiprazole; clozapine; olanzapine; quetiapine; risperidone
1448532581	CYP2D6*1; CYP2D6*2; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*17; CYP2D6*29; CYP2D6*35; CYP2D6*41; CYP2D6*43	PMCID:PMC4745369	CYP2D6	CYP2D6 *4/*4 + *5/*10 + *5/*41 are not associated with increased risk of Weight gain when treated with risperidone as compared to CYP2D6 *1/*1 + *1/*17 + *1/*2 + *2/*2 + *2/*43 + *1/*29 + *2/*41 + *35/*41.	no	> 0.05	24		Multiple groups, White and Black	Toxicity	false	CYP2D6 polymorphisms are not associated with adverse drug reactions (ADRs) (extrapyramidal symptoms (EPS) and weight gain.	risperidone
655388454	rs1414334	PMID:19142101	HTR2C	Allele C is associated with increased risk of Metabolic Syndrome when treated with clozapine and risperidone in people with Schizophrenia as compared to allele G.	yes		276		Unknown	Toxicity	false	(Odds ratios given but unable to access full text to get p values.)	clozapine; risperidone
1183492275	rs4483927	PMID:23422377	HRH4	Genotype TT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotypes GG + GT.	yes	= 0.006	112		East Asian	Efficacy	false	Patients with the TT genotype had a smaller reduction in positive, negative, general and total PANSS (Positive and Negative Syndrome Scale) scores after 4 and 8 weeks of treatment as compared to those with the GG or GT genotype. At 4 weeks, the TT genotype showed a significantly smaller reduction for all scores; at 8 weeks, it only showed a significantly smaller reduction for the positive and total scores. Please note that either ANOVA or Kruskal-Wallis tests were used, so all genotypes were compared against each other, and no post-hoc test information was provided.	risperidone
1184136878	SLC6A4 HTTLPR short form (S allele)	PMCID:PMC3619141	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased likelihood of Weight gain when treated with risperidone in people with Schizophrenia.	no	= 0.02	111		European	Toxicity	false	Authors state is non-significant trend. (Trend is reported for SLC6A4 S/S). Genotyping is done with the PHARMA Chip genotyping array.	risperidone
1450928193	rs1799978	PMCID:PMC5538123	DRD2	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1183491249	rs10514062	PMCID:PMC3845218	SV2C	Genotype TT is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AA + AT.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score. In significant LD (r2 > 0.95) with rs7732173 and rs2358531.	risperidone
1183491254	rs2358531	PMCID:PMC3845218	SV2C	Genotype GG is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AA + AG.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score. In significant LD (r2 > 0.95) with rs10514062 and rs7732173.	risperidone
1183702193	CYP2D6*1; CYP2D6*1xN; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:24329187	CYP2D6	CYP2D6 *4/*5 + *4/*6 + *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	yes	= 0.003	25		Unknown	Metabolism/PK	false	Poor metabolizers = homozygous for *3, *4, *5 or *6 variants (genotypes not specified- examples were given). Ultrarapid metabolizers = carries of the gene duplication who did not carry one of the above variants.	risperidone
1448999521	rs6318	PMID:19997080	HTR2C	Allele C is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to allele G.	yes	= 0.006	45		"Multiple groups, Portugal, 44 ""Caucasian"" 1 ""African"""	Toxicity	true	This gene is on the X chromosome.Those with no copies of the G allele (C males, there were no CC females in the cohort) had lower increases in prolactin compared to G males or GG females (there were no CG females).	risperidone
655388500	rs1799732	PMID:16513877	DRD2	Allele del is associated with increased time to respond when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype GG.	yes	< 0.03	61		Multiple groups, 41% African American; 28% Caucasian (European); 18% Hispanic; 5% Asian; 8% other	Efficacy	false	olanzapine (2.5 to 20 mg/day, N=28) or risperidone (1to 6 mg, N=33) treatment	olanzapine; risperidone
655388504	rs1799978	PMID:16513877	DRD2	Allele C is associated with decreased time until response when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype TT.	yes	= 0.004	61		Multiple groups, 41% African American; 28% Caucasian (European); 18% Hispanic; 5% Asian; 8% other	Efficacy	false	olanzapine (2.5 to 20 mg/day, N=28) or risperidone (1to 6 mg, N=33) treatment	olanzapine; risperidone
1450815024	rs2636719	PMCID:PMC3922978	PPA2	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	yes	= 5.05E-07	159		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of G alleles present in a patient was positively associated with CGI-S score. Please note that this variant is in high linkage disequilibrium with rs2636697.	risperidone
1448998934	rs6318	PMID:20504252	HTR2C	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false	Groups compared were GG females plus G males vs CG females + CC females + C males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1183491271	rs6882321	PMCID:PMC3845218	SV2C	Genotype AA is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AC + CC.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	risperidone
1444698707	rs4586	PMID:24495780	CCL2	Genotypes CC + CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.	yes	= 0.001	95		East Asian	Efficacy	false	Patients with the CC or CT genotype had a greater reduction in total Positive and Negative Symptom Scores (PANSS), as well as on the Positive and General subscales, at week 4 of risperidone treatment, as compared to those with the TT genotype. No significant results were seen when considering the Negative subscale. Additionally, significant results were only seen for one of the two cohorts studied, a population from Henan; no significant results were in a population from Shanghai (n=113).	risperidone
1450815030	rs7395555	PMCID:PMC3922978		Allele C is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	yes	= 1.98E-07	90		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of C alleles present in a patient was negatively associated with CGI-S score.	risperidone
1296599320	rs1045642	PMID:24589909	ABCB1	Genotypes AA + AG is associated with increased electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia as compared to genotype GG.	yes	= 0.003	66		East Asian	Toxicity	false	The AA and AG genotypes were significantly associated with increased QTc interval in stepwise multiple regression analysis (along with body weight and age). No significant differences in risperidone dose, plasma risperidone levels or plasma 9-hydroxyrisperidone levels were seen between the genotypes (p > 0.05). Please note that alleles have been complemented to the plus chromosomal strand.	risperidone
1450928170	rs1176713	PMCID:PMC5538123	HTR3A	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1449753147	rs887829	PMID:29955115	UGT1A1	Genotype CT is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype CC.	yes	= 0.014	33	51	Unknown	Toxicity	true	This SNP is also known as UGT1A1*80. This variant was in complete linkage disequilibrium with rs10929302 and rs1976391.	risperidone
1448998926	rs7566605	PMID:20504252	INSIG2	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1183702234	CYP2D6*1; CYP2D6*1xN; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:24329187	CYP2D6	CYP2D6 *4/*5 + *4/*6 + *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased wakefulness activity level when treated with risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	yes	= 0.021	25		Unknown	Other	false	Pooetabolizers = homozygous for *3, *4, *5 or *6 variants (genotypes not specified- examples were given). Ultrarapid metabolizers = carries of the gene duplication who did not carry one of the above variants.	risperidone
1450815009	rs2980976	PMCID:PMC3922978	TNFRSF11A	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	yes	= 2.97E-07	159		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of A alleles present in a patient was positively associated with CGI-S score.	risperidone
1450928162	rs1128503	PMCID:PMC5538123	ABCB1	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1444698694	rs4795893	PMID:24495780	CCL2	Genotypes AA + AG is associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.	yes	= 1.66E-4	95		East Asian	Efficacy	false	Patients with the AA or AG genotype had a greater reduction in total Positive and Negative Symptom Scores (PANSS), as well as on the Positive and General subscales, at week 4 of risperidone treatment, as compared to those with the GG genotype. No significant results were seen when considering the Negative subscale. Additionally, significant results were only seen for one of the two cohorts studied, a population from Henan; no significant results were in a population from Shanghai (n=113).	risperidone
1448998918	rs17047764	PMID:20504252	INSIG2	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1183615697	rs1045642	PMID:24026091	ABCB1	Genotypes AA + AG are associated with tendency toward greater improvement in PANSS-T when treated with risperidone in people with Schizophrenia as compared to genotype GG.	not stated	= 0.036	75		Unknown	Efficacy	false	association was found using PANSS-T (Positive and Negative Syndrome Scale-total) change.	risperidone
1450815015	rs2636697	PMCID:PMC3922978	PPA2	Allele G is associated with decreased response to risperidone in people with Schizophrenia as compared to allele A.	yes	= 3.68E-07	159		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of G alleles present in a patient was positively associated with CGI-S score. Please note that this variant is in high linkage disequilibrium with rs2636719.	risperidone
1448530486	CYP2D6*1; CYP2D6*2; CYP2D6*4; CYP2D6*5; CYP2D6*10	PMID:26944100	CYP2D6	CYP2D6 *4/*10 + *5/*10 are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.	yes	< 0.05	15		East Asian	Metabolism/PK	true	Genotyped with Luminex xTAG CYP2D6 Kit v3, which can identify *1, *2, *35,*9, *10, *17, *29, *41, *3, * 4, *5, *6, *7, *8, *11, *15, and duplications. The plasma concentration of risperidone in subjects with AS=0.5 (n=7) (4.12 ng/ml) was significantly higher than AS=2 (n=8) (0.13 ng/ml, P = 0.004) phenotype. The plasma concentration of risperidone/9-hydroxyrisperidone ratio in subjects with AS=0.5 (0.82) phenotype was significantly higher than AS=2 (0.02, P = 0.002).	risperidone
1183620333	CYP2D6*1; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*14	PMCID:PMC1884506	CYP2D6	CYP2D6 *4 + *5 + *10 +*14 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	yes	= 0.001	85		East Asian	Metabolism/PK	false	This study evaluated patients with *1, *4, *5, *10, and *14 alleles. A gene dose effect was observed in that with increasing numbers of variant alleles, higher concentrations of risperidone were seen. Concentrations of the major metabolite, 9-OH-risperidone, and active moiety, risperidone + 9-OH-risperidone, correlated with age, but not with CYP2D6 genotype.	risperidone
1448999487	rs6318	PMID:19997080	HTR2C	Genotype GG is associated with increased severity of Weight gain when treated with risperidone in children with Autistic Disorder as compared to allele C.	yes	= 0.037	45		"Multiple groups, Portugal, 44 ""Caucasian"" 1 ""African"""	Toxicity	true	This gene is on the X chromosome. Compared with the HTR2C GG homozygotes, patients with the variant genotype (C/C in females; C in males) have 4.6 and 2.8% smaller increases in waist circumference and BMI, respectively.	risperidone
827828530	rs324420	PMID:20631561	FAAH	Allele A is associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	yes	= 0.002	83		European	Toxicity	false	weight gain of more than 7% of baseline body weight	aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1296599341	CYP2D6*5; CYP2D6*10	PMID:24589909	CYP2D6	CYP2D6 *10 + *5 are not associated with electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia.	no	> 0.05	66		East Asian	Toxicity	false	Only CYP2D6*10 and *5 alleles were genotyped for. All other alleles were considered wild-type. Patients were divided based on whether they had 0, 1 or 2 of these variant alleles. No significant difference in QTc interval length was seen between patients who had 0, 1 or 2 variant alleles.	risperidone
1450928156	rs4680	PMCID:PMC5538123	COMT	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	no	> 0.05	288		East Asian	Efficacy	false	The A allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
1444698740	rs2857657	PMID:24495780	CCL2	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	yes	= 0.004	113		East Asian	Efficacy	false	Patients with the GG genotype had a greater reduction in Positive and Negative Symptom Scores (PANSS), specifically the Positive subscale, at weeks 4 and 8 of risperidone treatment, as compared to those with the CC and CG genotype. No significant results were seen when considering the Negative or General subscales, or the total PANSS score reduction. Additionally, significant results were only seen for one of the two cohorts studied, a population from Shanghai; no significant results were in a population from Henan (n=95).	risperidone
827814205	rs1042713	PMCID:PMC3619141	ADRB2	Allele G is associated with increased likelihood of Sexual adverse events when treated with risperidone in people with Schizophrenia as compared to allele A.	yes	= 0.002	111		European	Toxicity	false	(Association reported for ADRB2 16Gly)	risperidone
1450928144	rs4818	PMCID:PMC5538123	COMT	Allele G is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	no	> 0.05	288		East Asian	Efficacy	false	The G allele was initially significantly more frequent in patients designated as responders to risperidone (i.e. >50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
827828539	rs1049353	PMID:20631561	CNR1	Allele T is not associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	no	= 0.7	83		European	Toxicity	false	weight gain of more than 7% of baseline body weight	aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1183620832	CYP2D6*1; CYP2D6*10	PMID:16833023	CYP2D6	CYP2D6 *10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1.	yes	= 0.01	24		East Asian	Metabolism/PK	false	Subjects carrying the *10 allele showed significantly higher metabolic ratios (risperidone:9-OH-risperidone) and serum concentrations of risperidone as compared to subjects with the *1/*1 genotype. No difference was seen between CYP2D6 genotype and concentration of the active moiety (risperidone + 9-OH-risperidone), suggesting that CYP2D6 may be of limited importance for clinical outcome of risperidone treatment.	risperidone
1296599333	rs2032582	PMID:24589909	ABCB1	Genotype CC is not associated with electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia as compared to genotypes AC + CT.	no	> 0.05	66		East Asian	Toxicity	false	or TT + AT + AA. No significant difference in QTc interval length was seen between the three genotype groups. Additionally, no significant differences in risperidone dose, plasma risperidone levels or plasma 9-hydroxyrisperidone levels were seen between the genotypes. Please note alleles have been complemented to the plus chromosomal strand.	risperidone
1450814996	rs8050896	PMCID:PMC3922978		Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele A.	yes	= 3.85E-08	159		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of T alleles present in a patient was negatively associated with CGI-S score.	risperidone
1450928150	rs4633	PMCID:PMC5538123	COMT	Allele T is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	no	> 0.05	288		East Asian	Efficacy	false	The T allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
1450823692	rs2514218	PMCID:PMC4601717	DRD2	Genotype CC is not associated with severity of extrapyramidal symptoms due to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.	no	> 0.1	100		Multiple groups, Asian, African American, Hispanic, Caucasian and Other ethnicities.	Toxicity	true	No significant association between this variant and EPS score over 12 weeks of treatment.	aripiprazole; risperidone
1450928129	rs362306	PMCID:PMC5538123	HTT	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	no	> 0.05	288		East Asian	Efficacy	false	The A allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
1450928135	rs2515641	PMCID:PMC5538123	CYP2E1	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	no	> 0.05	288		East Asian	Efficacy	false	The T allele was initially significantly more frequent in patients designated as responders to risperidone (i.e. >50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
1446898364	rs489693	PMID:23920449	MC4R	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	yes	= 0.017	86		Unknown	Other	false	The authors analyzed the whole population of all patients administered one of many anti-psychotics, then a subpopulation without additional weight gain-inducing co-medication (adjusted sub-population)(weight-gaining co-meds included TCA, mirtazapine, lithium, valproic acid, and paroxetine) as well as a sub-group of patients for whom anti-psychotics were given for a first episode.The authors calculated adjusted means for weight gain 4 wk post-initiation of medication using ANCOVA and rs489693 genotype as a independent variable. Patients with the AA genotype had between 2.2–3.1 higher increase in weight gain vs. patients with the CC genotype.	amisulpride; clozapine; olanzapine; paliperidone; quetiapine; risperidone
1448639707	rs7412	PMCID:PMC5600660	APOE	Allele C is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele T.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1183699464	CYP3A7*1A; CYP3A7*1C	PMID:23609392	CYP3A7	CYP3A7 *1C is not associated with clearance of risperidone in people with Psychotic Disorders as compared to CYP3A7 *1A.	no		42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No association was found between this * allele and risperidone, 9-hydroxy-risperidone or active moiety plasma levels, risperidone/9-hydroxy-risperidone ratio, or dose requirements (data not shown).	risperidone
1451550220	rs362719	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no	= 0.732	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1183699460	rs776746	PMID:23609392	CYP3A5	Allele C is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele T.	no		42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No association was found between this SNP and risperidone, 9-hydroxy-risperidone or active moiety plasma levels, risperidone/9-hydroxy-risperidone ratio, or dose requirements (data not shown).	risperidone
1448266456	rs776746	PMID:26129906	CYP3A5	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1448639698	rs429358	PMCID:PMC5600660	APOE	Allele C is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele T.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1448530650	CYP2D6*1; CYP2D6*10	PMID:15729081	CYP2D6	CYP2D6 *10/*10 is not associated with response to risperidone in people with Schizophrenia as compared to CYP2D6 *1/*1.	no	> 0.05	39		East Asian	Efficacy,Toxicity	false	No difference was found among each genotype with respect to the clinical response measured with the Positive and Negative Syndrome Scale (PANSS) and extrapyramidal symptoms (Simpson and Angus (SAS)) during risperidone treatment.	risperidone
1183699485	rs2032582	PMID:23609392	ABCB1	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele C.	no	> 0.1	42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No association was found between this SNP and dose-adjusted plasma levels of risperidone, 9-hydroxy-risperidone or active moiety, risperidone/9-hydroxy-risperidone ratio, or dose requirements. Please note alleles have been complemented to the plus chromosomal strand.	risperidone
1183960064	CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:22592207	CYP2D6	CYP2D6 *4/*4 + *4/*5 + *4/*6 (assigned as poor metabolizer phenotype) is associated with increased risk of side effects when treated with risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.	no	= 0.06291	35		Unknown	Efficacy	false	Due to low number IM and EM patients were pooled. No explanation of how metabilzers were assigned, no diplotypes reported. The following alleles were presented *1, *2, *4, *5, *6, *9, *10, *27, *33, *41. One UM patient was found but exlcluded from analysis. Co-medication with other antipsychotics was allowed. side effects were measured with autonomic UKU sub-scale.	risperidone
1448639689	rs699	PMCID:PMC5600660	AGT	Allele G is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele A.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1183621150	rs6313	PMID:16633140	HTR2A	Genotype GG is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotypes AA + AG.	yes	= 0.0001	123		East Asian	Toxicity	false	This SNP was presented as 5-HT2a 102-T/C. Patients with the GG genotype showed less weight gain during treatment with risperidone as compared to patients carrying the A allele.	risperidone
1183699481	rs1128503	PMID:23609392	ABCB1	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.	no	> 0.1	42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No association was found between this SNP and dose-adjusted plasma levels of risperidone, 9-hydroxy-risperidone or active moiety, risperidone/9-hydroxy-risperidone ratio, or dose requirements. Please note alleles have been complemented to the plus chromosomal strand.	risperidone
1448266438	rs2740574	PMID:26129906	CYP3A4	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1449005259	rs2231142	PMID:28719598	ABCG2	Genotypes GT + TT is associated with decreased dose-adjusted trough concentrations of risperidone in children as compared to genotype GG.	yes	= 0.007	64		European	Metabolism/PK	true	Alleles complemented to plus chromosomal strand.	risperidone
1451550226	rs7341475	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	no	= 0.978	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1183699477	rs1045642	PMID:23609392	ABCB1	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.	no	> 0.1	42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No association was found between this SNP and dose-adjusted plasma levels of risperidone, 9-hydroxy-risperidone or active moiety, risperidone/9-hydroxy-risperidone ratio, or dose requirements. Please note alleles have been complemented to the plus chromosomal strand.	risperidone
1183960074	CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:22592207	CYP2D6	CYP2D6 *4/*4 + *4/*5 + *4/*6 (assigned as poor metabolizer phenotype) is not associated with differences in remission rate when treated with risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.	no	= 0.06291	35		Unknown	Efficacy	false	Due to low number IM and EM patients were pooled. No explanation of how metabilzers were assigned, no diplotypes reported. The following alleles were presented *1, *2, *4, *5, *6, *9, *10, *27, *33, *41. One UM patient was found but exlcluded from analysis. Co-medication with other antipsychotics was allowed.	risperidone
1451550232	rs39339	PMCID:PMC7005197	RELN	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.841	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
981500957	rs25531	PMID:20031235	SLC6A4	Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T.	no		147		European	Efficacy	false	6 week response was assessed.	antipsychotics; haloperidol; olanzapine; risperidone
1448266447	rs4646437	PMID:26129906	CYP3A4	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1451099363	CYP2D6*1; CYP2D6*2; CYP2D6*10	PMID:30870237	CYP2D6	CYP2D6 *10 is not associated with risk of Psychotic Disorders due to risperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.	no		36		Unknown	Toxicity	false	Patients carrying the *10 allele had a lower rate of episodes of dopamine supersensitivity psychosis than those carrying only the *1 or *2 alleles. However, this difference was not statistically significant. Note that some patients in the *10 group were identified as having a CYP2D6 duplication however the duplicated allele was not identified.	risperidone
1448998653	rs1045642	PMID:18718676	ABCB1	Allele A is associated with increased Weight gain when treated with risperidone in women with Schizophrenia as compared to allele G.	yes	= 0.015	23	24	European	Toxicity	false	Alleles complemented to plus chromosomal strand. Significant for risperidone only subset not risperidone or olanzapine.	risperidone
1448266483	rs7643645	PMID:26129906	NR1I2	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1451550247	rs3808035	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	no	= 0.695	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1449000697	rs1799978	PMCID:PMC4736591	DRD2	Genotype CT is associated with increased likelihood of Insulin Resistance when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotype TT.	yes	= 0.010	22	98	Multiple groups, Brazilian mixed	Toxicity	true	No CC homozygotes were observed. Alleles complemented.	risperidone
1451550241	rs3819479	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.529	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1184748603	CYP2C19*1; CYP2C19*2; CYP2C19*4	PMID:25042870	CYP2C19	CYP2C19 *1/*1 + *1/*2 is associated with increased likelihood of Neurologic Manifestations when treated with risperidone in healthy individuals as compared to CYP2C19 *2/*2 + *2/*4.	yes	= 0.008	70		Multiple groups, 67 Caucasian, 3 Hispanic	Toxicity	false	Individuals with the *1/*1 and *1/*2 genotypes more frequently showed neurological adverse effects (those with the *2/*2 and *2/*4 genotypes showed no neurological adverse effects). This result was statistically significant in multiple regression analysis.	risperidone
1449189063	CYP2D6*1; CYP2D6*4; CYP2D6*41	PMCID:PMC5810290	CYP2D6	CYP2D6 *4 + *41 are associated with Binge eating disorder, Constipation, Dystonia, extrapyramidal symptoms, Galactorrhea, Psychomotor Agitation and Weight gain when treated with aripiprazole, quetiapine and risperidone in children with Schizophrenia as compared to CYP2D6 *1.	not stated		1		Unknown	Other	true		aripiprazole; quetiapine; risperidone
1451550253	rs2535764	PMCID:PMC7005197	RELN	Allele T is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no	= 0.179	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
981477934	rs3813929	PMID:17702092	HTR2C	Allele T is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele C.	no		139		Unknown	Toxicity	false	This SNP was studied in conjunction with rs6318 and a repeat polymorphism in the 5' flanking region [(GT)12-18/(CT)4-5].  None of the three variants were associated with increased risk of weight gain when studied alone.  When studied as a combination, only one combination, the long-C-Ser (repeat-rs3813929-rs6318), was associated with a protective effect against weight gain.  However, effect and sample sizes were small (n=13). This gene is on the X chromosome therefore males have one copy, the percentages of males in the study size was not reported.	clozapine; haloperidol; olanzapine; risperidone
1448266492	rs4253728	PMID:26129906	PPARA	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1449000685	rs1065852	PMCID:PMC4736591	CYP2D6	Genotype AA is associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AG + GG.	yes	= 0.028	120		Multiple groups, Brazilian mixed	Toxicity	true	Corrigendum gives rs1065852 as the CYP2D6 allele that was measured. Table described this as for Presence of allele C vs Absence of allele C, complemented here to plus chromosomal strand.	risperidone
1183621181	rs1805054	PMID:16633140		Genotype TT is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 0.02	123		East Asian	Toxicity	false	This SNP was presented as 5-HT6 267-T/C. Patients with the TT genotype showed less weight gain during treatment with risperidone as compared to patients carrying the C allele.	risperidone
1183699519	rs7643645	PMID:23609392	NR1I2	Genotype GG is associated with decreased active moiety levels when treated with risperidone in people with Psychotic Disorders as compared to genotype AA.	yes	= 0.001	57		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	Patients with the GG genotype had 2.8-fold lower active moiety compared to those with the AA genotype. This was assessed in an original cohort (n=42) and a replication cohort (n=16; 2.5-fold lower), and then in the two cohorts combined (n=57). Psychotic disorders consisted of schizoaffective disorder and schizophrenia.	risperidone
1448998639	rs3813929	PMID:18718676	HTR2C	Allele T is not associated with increased Weight gain when treated with olanzapine or risperidone in women with Schizophrenia as compared to allele C.	no	= 0.057	49	59	European	Toxicity	false	HTR2C gene is x-linked, study was performed in women only.	olanzapine; risperidone
1448266465	rs1057868	PMID:26129906	POR	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1451099341	CYP2D6*1; CYP2D6*2; CYP2D6*10	PMID:30870237	CYP2D6	CYP2D6 *10 is not associated with concentrations of risperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.	no		36		Unknown	Metabolism/PK	false	Risperidone plasma concentrations were higher in patients carrying the *10 allele than in those carrying only the *1 or *2 alleles, however this difference was not statistically significant. Note that some patients in the *10 group were identified as having a CYP2D6 duplication however the duplicated allele was not identified.	risperidone
981477941	rs6318	PMID:17702092	HTR2C	Allele C is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele G.	no		139		Unknown	Toxicity	false	This SNP was studied in conjunction with rs3813929 and a repeat polymorphism in the 5' flanking region [(GT)12-18/(CT)4-5].  None of the three variants were associated with increased risk of weight gain when studied alone.  When studied as a combination, only one combination, the long-C-Ser (repeat-rs3813929-rs6318), was associated with a protective effect against weight gain.  However, effect and sample sizes were small (n=13). This gene is on the X chromosome therefore males have one copy, the percentages of males in the study size was not reported.	clozapine; haloperidol; olanzapine; risperidone
1183629369	rs1800497	PMID:23859574	ANKK1	Genotypes AA + AG are associated with increased Neurotoxicity Syndromes when treated with risperidone in healthy individuals as compared to genotype GG.	not stated	= 0.049	70		European	Toxicity	false	Individuals with the DRD2 A1/A1 or A1/A2 genotype more frequently developed neurological adverse reactions (75 and 78%) vs A2/A2 (49%). Here allele A is used to represent A1 which is less frequent in Caucasian populations  and G to represent A2 which is the major allele in Caucasians). Statistics did not mention correction for multiple testing.	risperidone
1183619642	CYP2D6*1; CYP2D6*4; CYP2D6*5	PMID:10639689	CYP2D6	CYP2D6 *4 + *5 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	yes	= 0.05	37		European	Metabolism/PK	false	In this study, patients classified as poor metabolizers were found to have the *4/*5 genotype. These patients had significantly higher risperidone/9-OH-risperidone ratios and concentration/dose ratios as compared to all other patients. Patients carrying one defective and one wild-type allele (*1/*4 or *1/*5) also had higher metabolic and C/D ratios as compared to patients with the *1/*1 or *1xN/*1 genotype.	risperidone
1451550259	rs12705169	PMCID:PMC7005197	RELN	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.596	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448266474	rs2472677	PMID:26129906	NR1I2	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1183699510	rs7643645	PMID:23609392	NR1I2	Genotype GG is associated with decreased 9-hydroxy-risperidone levels when treated with risperidone in people with Psychotic Disorders as compared to genotype AA.	yes	= 0.018	57		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	Patients with the GG genotype had 2.6-fold lower dose-adjusted levels of 9-hydroxy-risperidone compared to those with the AA genotype. This was assessed in an original cohort (n=42) and a replication cohort (n=16; 2.5-fold lower), and then in the two cohorts combined (n=57). Psychotic disorders consisted of schizoaffective disorder and schizophrenia.	risperidone
1451550271	rs362626	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	no	= 0.394	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1183621168	rs3813929	PMID:16633140	HTR2C	Genotypes CT + TT is associated with decreased severity of Weight gain due to risperidone in people with Schizophrenia as compared to genotype CC.	yes	= 0.04	123		East Asian	Toxicity	false	This SNP was presented as 5-HT2c -759-C/T, it is on the X chromosome therefore men have only one copy. Patients with the variant T allele (TT and CT women plus T men)  showed less weight gain during treatment with risperidone as compared to patients without the T allele (CC women and C men).	risperidone
1451550265	rs2237628	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.160	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1447959180	CYP2D6*1; CYP2D6*2; CYP2D6*10; CYP2D6*87; CYP2D6*88; CYP2D6*89; CYP2D6*90; CYP2D6*91; CYP2D6*93; CYP2D6*94; CYP2D6*95; CYP2D6*97; CYP2D6*98	PMID:26544071	CYP2D6	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of risperidone as compared to CYP2D6 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	The the conversion of risperidone to 9-OH risperidone was measured for *2 (R296C, S486T); *10 (P34S, S486T); *87 (A5V); *88 (V104A); *89 (L142S); *90 (K147R); *91 (C161S); *93 (T249P); *94 (D337G); *95(R388H); *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance as % of *1: *2: 26.56; *10: 2.01; *87: 43.30; *88: 75.86; *89: 87.56; *90: 78.40; *91: 85.37; *93: 9.62; *94: 78.92; *95: 46.85; *97: 53.99; *98: 64.47 No information about *1 construct but might be cDNA.Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.	risperidone
1450928312	rs9606186	PMCID:PMC5538123	COMT	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	no	= 0.511	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1448266389	rs35599367	PMID:26129906	CYP3A4	Genotype AG is associated with decreased clearance of risperidone in people with as compared to genotype GG.	yes	= 8.0E-3	150		Multiple groups, 81% caucasian	Metabolism/PK	false	Clearance of 9-OH risperidone was 30% lower than in GG individuals.	risperidone
1183699525	rs7643645	PMID:23609392	NR1I2	Genotype AA is not associated with clearance of risperidone in people with Psychotic Disorders as compared to genotype GG.	no	= 0.130	42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No significant difference in dose-adjusted plasma levels of risperidone were seen between the genotypes.	risperidone
1447949447	rs2069062	PMCID:PMC4872428	GRM7	Genotype CC is associated with increased response to risperidone in people with as compared to genotypes CG + GG.	yes	< 0.05	86		Multiple groups	Efficacy	false	Psychotic-naive or minimal antipsychotic exposure. Improvement measured with Brief Psychiatric Rating Scale.	risperidone
1446898423	rs646749	PMCID:PMC4166499		Allele A is not associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no	= 3.09E-7	139		Unknown	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
1451550286	rs362813	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.903	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448998550	rs2032582	PMID:20195292	ABCB1	Genotype AA is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotypes AC + CC.	no	= 0.001	101		European	Toxicity	false	in fact A allele was slightly less common in patients without metabolic syndrome than with metabolic syndrome but there were significant increases in fasting blood glucose in AA homozygotes (particularly in olanzapine subset) and glucose dysregulation is a feature of metabolic syndrome. Alleles complemented to plus chromosomal strand.	olanzapine; risperidone
1450928304	rs6313	PMCID:PMC5538123	HTR2A	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1451550280	rs362814	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.973	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448993424	CYP3A4*1; CYP3A4*22	PMID:25868121	CYP3A4	CYP3A4 *22 is not associated with dose-adjusted trough concentrations of antipsychotics, aripiprazole, haloperidol, pimozide or risperidone in people with Psychotic Disorders as compared to CYP3A4 *1.	no	= 0.35	834		European	Metabolism/PK	false		antipsychotics; aripiprazole; haloperidol; pimozide; risperidone
769156872	rs2032582	PMID:21173786	ABCB1	Allele A is not associated with dose of risperidone as compared to allele C.	no	= 0.24	151		European	Dosage,Metabolism/PK	false		risperidone
1447945885	CYP2D6*1; CYP2D6*4	PMID:26872113	CYP2D6	CYP2D6 *4 is not associated with severity of Hyperprolactinemia when treated with risperidone in children with Schizophrenia as compared to CYP2D6 *1.	no		147		East Asian	Toxicity	true	only assessed *5, *4, *10, and *41 (rs3892097, rs1065852, rs28371725)	risperidone
1451550292	rs362731	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.134	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1184469067	rs7912580	PMID:24751813		Genotype AG is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype GG.	no	> 0.05	1406		Unknown	Efficacy	false	results did not reach significance.	olanzapine; quetiapine; risperidone; ziprasidone
769156875	rs776746	PMID:21173786	CYP3A; CYP3A5	Allele C is not associated with dose of risperidone as compared to allele T.	no	= 0.42	151		European	Dosage,Metabolism/PK	false		risperidone
1450928296	rs6311	PMCID:PMC5538123	HTR2A	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no	= 1	288		East Asian	Efficacy	false		risperidone
608431255	rs2842030	PMCID:PMC2194758	RGS4	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes GT + TT.	not stated		397		European	Efficacy	false	compared to perphenazine, quetiapine, and ziprasidone treatment	risperidone
1447681693	CYP2D6*1; CYP2D6*10; CYP2D6*41	PMID:26780783	CYP2D6	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*10 + *1/*41.	no	= 0.67	97		East Asian	Metabolism/PK	true	Measured after at least 4 weeks of treatment	risperidone
1446898411	rs489693	PMCID:PMC4166499	MC4R	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	yes	< 0.01	139		Unknown	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
1448266372	CYP2D6 poor metabolizer genotype	PMID:26129906	CYP2D6	CYP2D6 poor metabolizer genotype is associated with increased exposure to risperidone in people with Bipolar Disorder, Depression, Psychotic Disorders or Substance-Related Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer genotypes.	yes	< 0.0001	150		Multiple groups, 81% caucasian	Metabolism/PK	false		risperidone
1183619675	CYP2D6*1; CYP2D6*1xN	PMID:10639689	CYP2D6	CYP2D6 *1xN is associated with increased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	no	= 0.05	37		European	Metabolism/PK	false	Patients carrying a gene duplication of a functional allele were classified as ultrarapid metabolizers. These patients were found to have the lowest risperidone/9-OH-risperidone ratios and concentration/dose ratios as compared to all other patients. However, this difference was not significant when compared to patients with the *1/*1 genotype.	risperidone
1451099305	CYP2D6*1; CYP2D6*2; CYP2D6*10	PMID:30870237	CYP2D6	CYP2D6 *10 is not associated with dose of risperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.	no		36		Unknown	Dosage	false	No significant difference in average risperidone dose between patients carrying the *10 allele and those carrying only the *1 or *2 alleles. Note that some patients in the *10 group were identified as having a CYP2D6 duplication however the duplicated allele was not identified.	risperidone
1447949461	rs1875705	PMCID:PMC4872428	GRID2	Genotype GG is associated with increased response to risperidone in people with as compared to genotypes AA + AG.	yes	= 1.1E-8	86		Multiple groups	Efficacy	false	Psychotic-naive or minimal antipsychotic exposure. Improvement measured with Brief Psychiatric Rating Scale.	risperidone
1449189048	CYP2D6*1; CYP2D6*1xN	PMCID:PMC5810290	CYP2D6	CYP2D6 *1xN is associated with extrapyramidal symptoms, hepatic cytolysis and Weight gain when exposed to haloperidol, levomepromazine and risperidone in children with Schizophrenia as compared to CYP2D6 *1.	not stated		1		Unknown	Other	true		haloperidol; levomepromazine; risperidone
1183621205	rs1801028	PMID:16633140	DRD2	Genotype CG is not associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotype GG.	no	= 0.09	123		East Asian	Toxicity	false	This SNP was presented as D2 311-Ser/Cys. Patients heterozygous at this SNP showed a non-significant trend towards less weight gain during treatment with risperidone as compared to patients homozygous for the Ser allele. No patients homozygous for the Cys allele were found in this study.	risperidone
1451550301	rs362726	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.862	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1183629398	rs1806201	PMID:23859574	GRIN2B	Genotype GG is associated with increased general adverse reactions when treated with risperidone in healthy individuals as compared to genotypes AA + AG.	not stated	= 0.046	72		European	Toxicity	false	General adverse reactions to risperidone were more common in individuals with the GG genotype compared to those with the A allele. Alleles have been complemented to the plus chromosomal strand. Statistics did not mention correction for multiple testing.	risperidone
1450928288	rs6295	PMCID:PMC5538123	HTR1A	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	no	= 0.274	288		East Asian	Efficacy	false		risperidone
613979204	rs2661319	PMID:18204343	RGS4	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.	yes	= 0.001	120		East Asian	Efficacy	false		risperidone
1183629394	rs6313	PMID:23859574	HTR2A	Genotype AA is associated with increased likelihood of cardiovascular adverse reactions when treated with risperidone in healthy individuals as compared to genotypes AG + GG.	not stated	= 0.004	72		European	Toxicity	false	Cardiovascular adverse reactions were more frequent in individuals with the AA genotype (36%) vs those with the G allele (5%). Please note alleles have been complemented to the plus chromosomal strand. Statistics did not mention correction for multiple testing.	risperidone
1448998530	rs1045642	PMID:20195292	ABCB1	Genotypes AG + GG is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotype AA.	no	= 0.028	61		European	Toxicity	false	but there were significant increases in fasting blood glucose in olanzapine treated patients with the AG+GG genotypes and glucose dysregulation is a feature of metabolic syndrome. Alleles complemented to plus chromosomal strand.	olanzapine; risperidone
655387634	rs1799978	PMID:18855532	DRD2	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype CT.	yes	= 0.031	120		East Asian	Efficacy	false	Patients with the TT genotype had better improvement in total PANSS score than patients with the CT genotype.	risperidone
1450928280	rs6265	PMCID:PMC5538123	BDNF	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1446898393	rs489693	PMCID:PMC4166499	MC4R	Allele A is associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	yes	= 5.59E-12	344		Multiple groups	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
1449181828	rs1137101	PMID:29441581	LEPR; LEPROT	Genotype GG is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AA + AG.	no	= 0.816	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1449645187	rs1045642	PMID:29914302	ABCB1	Genotype AA is associated with increased severity of Hyperprolactinemia when treated with risperidone in women with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to genotypes AG + GG.	yes		49		"Multiple groups, Authors list 41/49 Caucasian, 7/49 African American, 1/49 other. "	Metabolism/PK	false	Alleles complemented to plus chromosomal strand. Opposite effect was seen in males. In females, the prolactin increase also correlated with plasma risperidone in males the prolactin increase correlated with plasma 9-OH risperidone. p value unclear.	risperidone
1447681711	CYP2D6*1; CYP2D6*5; CYP2D6*10; CYP2D6*41	PMID:26780783	CYP2D6	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*5 + *10/*10 + *10/*41.	no	= 0.08	97		East Asian	Metabolism/PK	true	Measured after at least 4 weeks of treatment	risperidone
1448266420	rs2276707	PMID:26129906	NR1I2	Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to genotypes CT + TT.	yes	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false	The clearance of risperidone was found to be 6% higher in patients with the CC genotype compared to patients with the CT and TT genotypes.	risperidone
982025839	rs1799732	PMID:18579277	DRD2	Allele G is not associated with increased risk of Hyperprolactinemia when treated with risperidone in people with Schizophrenia as compared to allele del.	no	= 0.232	174		East Asian	Toxicity	false		risperidone
655387128	rs951439	PMCID:PMC2194758	RGS4	Genotype TT is associated with increased likelihood of response when treated with risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes		397		European	Efficacy	false		risperidone
1448530620	CYP2D6*1; CYP2D6*10	PMID:20332423	CYP2D6	CYP2D6 *10/*10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.	yes	< 0.001	11		East Asian	Metabolism/PK	false	Genotyped for *4, *5, *14A, *10. Only *10 identified. AUC0-infinity for Risperidone and Risperidone/9-Hydroxyrisperidone were significantly different between diplotypes, while AUC0-infinity for 9-Hydroxyrisperidone and AUC0-infinity for the Active Moiety showed no differences.	risperidone
982025827	rs1800497	PMID:18579277	ANKK1	Allele A is not associated with increased risk of Hyperprolactinemia when treated with risperidone in people with Schizophrenia as compared to allele G.	no	= 0.693	174		East Asian	Toxicity	false		risperidone
1450928272	rs4483927	PMCID:PMC5538123	HRH4	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no	= 0.274	288		East Asian	Efficacy	false		risperidone
1449181836	rs2229109	PMID:29443543	ABCB1	Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.	yes					Metabolism/PK	false		amisulpride; aripiprazole; olanzapine; risperidone
1448639669	rs1799752	PMCID:PMC5600660	ACE	Allele del is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1451251823	CYP2D6 intermediate metabolizer phenotype	PMID:24232129	CYP2D6	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of risperidone as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .	yes	= 0.01	190		European	Metabolism/PK	false	Note: the association is reported for carriers of a def/red alleles or red/red alleles compared to patients with *1/def genotypes. The specific diplotype of the patients is not given. def: *3 (2549delA), *4 (1846 G>A), *5 (gene deletion), *6 (1707delT), red:*9 (2615_2617delAAG), *10 (100C>T), and *41 (2988 G>A). In the total cohort for both treatments 179 patients were carriers of CYP2D6*1/*1 genotype, 65 patients were carriers of CYP2D6*1/red genotype, 129 patients were carriers of CYP2D6*1/def genotype, 15 patients were carriers of CYP2D6*red/red genotype, 27 patients were carriers of CYP2D6def/red genotype, and 41 patients were carriers of CYP2D6def/def genotype. red/def genotypes are associated with increased median serum concentration of risperidone by 4.5 fold when treated with risperidone as compared to *1/def genotypes. red/red genotypes are associated with increased median serum concentration of risperidone by 3.4 fold when treated with risperidone as compared to *1/def genotypes.	risperidone
1448266403	rs1523130	PMID:26129906	NR1I2	Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression or Substance-Related Disorders as compared to genotypes CT + TT.	yes	= 0.01	150		Multiple groups, 81% Caucasian	Metabolism/PK	false	The clearance of risperidone was found to be 33% higher in patients with the CC genotype compared to patients with the CT and TT genotypes.	risperidone
1446898383	rs17782313	PMID:23920449	MC4R	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	yes	= 0.005	173		Unknown	Other	false	The authors analyzed the whole population of all patients administered one of many anti-psychotics, then a subpopulation without additional weight gain-inducing co-medication (adjusted sub-population) (weight-gaining co-meds included TCA, mirtazapine, lithium, valproic acid, and paroxetine) as well as a sub-group of patients for whom anti-psychotics were given for a first episode. The authors calculated adjusted means for weight gain 4 wk post-initiation of medication using ANCOVA and rs17782313 genotype as a independent variable.	amisulpride; clozapine; olanzapine; paliperidone; quetiapine; risperidone
1450928264	rs3818929	PMCID:PMC5538123	SLC44A3	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	no	= 1	288		East Asian	Efficacy	false	Please note that alleles have been complemented to the positive strand.	risperidone
1447681725	CYP2D6*1; CYP2D6*4; CYP2D6*5; CYP2D6*10	PMID:26780783	CYP2D6	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *4/*10 + *5/*10.	no	= 0.055	97		East Asian	Metabolism/PK	true	Measured after at least 4 weeks of treatment	risperidone
655387624	rs1799978	PMID:17105675	DRD2	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	yes	= 0.031	125		East Asian	Other	false		risperidone
1184469093	rs2412459	PMID:24751813	EIF2AK4	Genotype CT is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype TT.	no	> 0.05	1406		Unknown	Efficacy	false	results did not reach significance.	olanzapine; quetiapine; risperidone; ziprasidone
1447945904	rs1800497	PMID:26872113	DRD2	Genotypes AA + AG are associated with decreased severity of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype GG.	no	= 0.038	147		East Asian	Toxicity	true	"""DRD2 genotype frequencies were Taq1A A2A2 (38.77%), A1A2 (41.50%), and A1A1 (19.73%)""""DRD2 Taq1A A2A2 (17.80 ng/mL) was significantly higher than A1A2 (17.10 ng/mL) and A1A1 (12.70 ng/mL).""Authors do not define which base the term A2 describes but define it as ""A2A2 or wild type"", therefore interpreted A2 as G since it is the major allele in most populations."	risperidone
655387630	rs1799732	PMID:17105675	DRD2	Allele del is not associated with response to risperidone in people with Schizophrenia.	no		125		East Asian		false		risperidone
982025846	rs6280	PMID:18579277	DRD3	Allele T is not associated with increased risk of Hyperprolactinemia when treated with risperidone in people with Schizophrenia as compared to allele C.	no	= 0.926	174		East Asian	Toxicity	false		risperidone
1448530601	CYP2D6*1; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:20814331	CYP2D6	CYP2D6 *4/*4 + *4/*5 + *4/*6 are associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.	yes	< 0.05	40		European	Metabolism/PK	false	Single dose of 1 mg. Genotyped for *3, *4, *5, *6, *7, *9. The higher the AS, the lower AUC and half-life and the greater clearance. PM had higher values for AUC, Cmax, half-life time of risperidone and decreased clearance.	risperidone
1451432060	rs1801133	PMID:33858192	MTHFR	Genotype AG is associated with decreased clinical benefit to antipsychotics, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine or risperidone in women with Schizophrenia as compared to genotype GG.	yes	= 0.008	117		Near Eastern	Efficacy	false	"response is measured by PANSS (Positive and Negative Syndrome Scale), alleles complemented to plus chromosomal strand. In initial evaluation of whole cohort (men and women) authors stated ""A
significantly higher mean score was also found in those having MTHFR CT genotype compared with CC and TT
patients. "" ""Higher negative Positive and Negative Syndrome Scale scores were significantly associated with women and having the CT genotype for MTHFR c.677C>T (β = 4.25; p = 0.008) compared with CC patients. """	antipsychotics; chlorpromazine; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1446898493	rs1049353	PMCID:PMC3693401	CNR1	Allele C is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.	yes	= 1.29E-9	181		Unknown	Other	true	"Age corrected BMI increases over the 8 wk period after initiating risperidone were highest for the CT genotype as compared to the TT genotype.  This, is considered a ""risk allele"" for risperidone associated weight-gain. The authors calculated a risk score based on the number of risk alleles a patient carried. Two other SNPs (rs806378 T and rs7799039 G) were considered risk alleles. The authors estimated risk with allele dosage (0,1,2, or 3 risk alleles) and predicted weight gain in the overall sample."	risperidone
655387666	rs1800497	PMCID:PMC2699901	ANKK1	Genotypes AA + AG are associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to genotype GG.	yes	< 0.05	90		European	Toxicity	false		risperidone
655387669	rs1799978	PMCID:PMC2699901	DRD2	Allele C is associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to allele T.	yes	= 0.002	90		European	Toxicity	false		risperidone
1296599629	CYP2D6*5; CYP2D6*10	PMID:24589909	CYP2D6	CYP2D6 *10 + *5 are associated with increased concentrations of risperidone in people with Schizophrenia.	yes	< 0.001	66		East Asian	Metabolism/PK	false	Only CYP2D6*10 and *5 alleles were genotyped for. All other alleles were considered wild-type. Patients were divided based on whether they had 0, 1 or 2 of these variant alleles. Patients with 2 variant alleles had significantly higher plasma levels of risperidone as compared to those with no variant alleles.	risperidone
655387136	rs10917670	PMID:18204343	RGS4	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype CC.	no					Efficacy	false	did not significantly influence end-point scores of any scale after Bonferroni correction for multiple comparisons	risperidone
1183620508	CYP2D6*1; CYP2D6*4	PMID:15565299	CYP2D6	CYP2D6 *4 is not associated with decreased response to risperidone in people with Schizophrenia as compared to CYP2D6 *1.	no		82		Unknown	Efficacy	false	Response to risperidone was not associated with CYP2D6 genotype.	risperidone
1446898478	rs806378	PMCID:PMC3693401	CNR1	Allele T is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.	yes	= 1.29E-9	181		Unknown	Other	true	"Age corrected BMI increases over the 8 wk period after initiating risperidone were as follows: CC=1.34, CT=1.57, TT=1.85.  This, is considered a ""risk allele"" for risperidone associated weight-gain. The authors calculated a risk score based on the number of risk alleles a patient carried. Two other SNPs (rs1049353 G and rs7799039 G) were considered risk alleles. The authors estimated risk with allele dosage (0,1,2, or 3 risk alleles) and predicted weight gain in the overall sample."	risperidone
1447945041	rs7799039	PMCID:PMC4736591	LEP	Genotype GG is associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AA + AG.	yes	= 0.007	120		Multiple groups, Brazilian mixed	Toxicity	true		risperidone
981501343	rs3813929	PMCID:PMC3003450	HTR2C	Allele T is associated with decreased likelihood of Weight gain when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype CC.	yes	< 0.001	32		European	Toxicity	true	Weight gain also appeared to be associated with higher dose and younger age.  Weight gain was assessed at 8 wks. This gene is on the X chromosome. There were 7 children that carried the T allele 4 males (T genotype) and 3 females (genotypes not specified, may be TT or CT)	risperidone
1451484060	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	PMID:32519344	CYP2D6	CYP2D6 poor metabolizer and intermediate metabolizer genotypes is associated with increased exposure to risperidone in people with Psychotic Disorders or Schizophrenia as compared to CYP2D6 normal metabolizer genotype.	yes	< 0.0001	1934		Multiple groups	Metabolism/PK	false		risperidone
1448530802	CYP2D6 poor metabolizers	PMID:24828442	CYP2D6	CYP2D6 poor metabolizers are associated with decreased metabolism of risperidone in children as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	yes	< 0.05	38		Unknown	Metabolism/PK	true	PM (n=2) showed higher risperidone plasma level (p=0.03) and increased  metabolic ration (risperidone/9-hydroxyrisperidone) (p=0.004) compared to intermediate and normal metabolizers combined (n=36).	risperidone
981501350	rs1414334	PMCID:PMC3003450	HTR2C	Allele C is not associated with likelihood of Weight gain when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype GG.	no	= 0.16	32		European	Toxicity	true	Weight gain was assessed at 8 wks. This gene is on the X chromosome. There were only 5 children that carried the C allele and all were male i.e C genotype. No CC or CG females.	risperidone
1448604016	rs2235048	PMCID:PMC5563830	ABCB1	Genotypes AG + GG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype AA.	yes	= 0.033	171		East Asian	Efficacy	false	Alleles given as reverse strand C and T. Efficacy measured with reduction in PANSS total score reduced rate.	risperidone
1183620517	CYP2D6*1; CYP2D6*10	PMID:17715206	CYP2D6	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	yes	= 0.012	118		East Asian	Efficacy,Metabolism/PK	false	A gene dose effect was seen in that with increasing numbers of the *10 allele, patients showed increasing ratios of risperidone:9-OH-risperidone. No differences were seen between CYP2D6 genotype and concentrations of the active moiety (risperidone+9-OH-risperidone), concentrations of 9-OH-risperidone, or clinical response.	risperidone
1448604030	rs1045642	PMCID:PMC5563830	ABCB1	Genotypes AA + AG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.	no	= 0.081	171		East Asian	Efficacy	false	Alleles given as reverse strand C and T. Efficacy measured with reduction in PANSS total score reduced rate.	risperidone
1448255358	rs1414334	PMCID:PMC4941738	HTR2C	Allele C is not associated with risk of Metabolic Syndrome when treated with amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone or ziprasidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to allele G.	no	= 0.164	68	98	European	Toxicity	false	Because HTR2C is on the X chromosome, men and women were analyzed separately.	amisulpride; aripiprazole; clozapine; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
699638917	rs165599	PMID:19451915	COMT	Allele G is associated with increased response to risperidone in people with Schizophrenia.	yes	= 0.032	143		Multiple groups, 78 African American and 65 white patients	Efficacy	false		risperidone
982015423	rs3813928	PMID:17632216	HTR2C	Allele A is not associated with likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	no		112		European	Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors. There was complete LD between rs3813928 ( – 997) A allele and the rs3813929 ( – 759) T allele.	antipsychotics; clozapine; olanzapine; risperidone
699638922	rs724226	PMID:19451915	GRM3	Allele G is associated with increased response to risperidone in people with Schizophrenia.	yes	= 0.016	143		Multiple groups, 78 African American and 65 white patients	Efficacy	false		risperidone
1183699383	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5	PMID:23609392	CYP2D6	CYP2D6 ultrarapid metabolizer phenotype is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .	yes	= 0.006	42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	Ultrarapid metabolizers (UM) were designated as *1/*XN or *XN/*XN. Intermediate metabolizers (IM) were designated as the genotypes above, as well as *4/*XN. Patients with the UM phenotype had 45% the dose-adjusted plasma concentration of risperidone compared to those with the IM phenotype (adjusted for dose, age and sex). Patients with the UM phenotype also had 36% the risperidone/9-hydroxy-risperidone ratio compared to those with the IM phenotype (adjusted for age and sex). No significant associations were seen when considering dose-adjusted 9-hydroxy-risperidone levels or active moiety.	risperidone
982015415	rs1414334	PMID:17632216	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	yes	= 0.042	112		European	Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two: although sex by genotype interaction was not significant males with risk haplotype that included this variant had higher OR than females. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors.	antipsychotics; clozapine; olanzapine; risperidone
1446898434	rs12970134	PMCID:PMC4166499		Allele A is not associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no	= 3.26E-6	139		Unknown	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
1183918545	CYP2D6*1; CYP2D6*1xN	PMID:22775532	CYP2D6	CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype phenotype) is not associated with differences in treatment response or scores on the various subscales of the PANSS when treated with haloperidol or risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.	no	> 0.05	35		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05).  22EM and 2 UMAmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	haloperidol; risperidone
655387218	rs6280	PMID:19997080	DRD3	Genotypes CC + CT is associated with increased response to risperidone in children with Autistic Disorder as compared to genotype TT.	yes	= 0.012	45		Multiple groups, Portugal: 44 white, 1 african	Efficacy	true	as measured by decrease in ATEC score.	risperidone
1448266512	rs9282564	PMID:26129906	ABCB1	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
982015435	rs518147	PMID:17632216	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	no	= 0.049	112		European	Other,Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two: although sex by genotype interaction was not significant males with risk haplotype that included this variant had higher OR than females. This variant was not significant alone for risk of Metabolic Syndrome after bonferroni correction, but waist circumference was significant. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors.	antipsychotics; clozapine; olanzapine; risperidone
1446898553	rs6499640	PMCID:PMC3693401	FTO	Allele G is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele A.	no	= 0.88	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1449000725	rs6318	PMCID:PMC4736591	HTR2C	Genotype CG are associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders.	not stated	= 0.035	120		Multiple groups, Brazilian mixed	Toxicity	true	This gene is on the X chromosome and analysis was for C,CC vs CG, vs G, GG	risperidone
1448266521	rs2229109	PMID:26129906	ABCB1	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
982015429	rs3813929	PMID:17632216	HTR2C	Allele C is not associated with likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele T.	no		112		European	Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors. There was complete LD between rs3813928 ( – 997) A allele and the rs3813929 ( – 759) T allele.	antipsychotics; clozapine; olanzapine; risperidone
1446898546	rs1421085	PMCID:PMC3693401	FTO	Allele C is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.	no	= 0.13	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1448998669	rs2032582	PMID:18718676	ABCB1	Allele A is associated with increased Weight gain when treated with risperidone in women with Schizophrenia as compared to allele C.	yes	= 0.031	23	24	European	Toxicity	false	Alleles complemented to plus chromosomal strand. Significant for risperidone only subset not risperidone or olanzapine. Authors call this borderline significant.	risperidone
1449000717	rs1065852	PMCID:PMC4736591	CYP2D6	Genotype AA is associated with increased likelihood of Hypertension when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AG + GG.	yes	= 0.039	8	112	Multiple groups, Brazilian mixed	Toxicity	true	Corrigendum gives rs1065852 as the CYP2D6 allele that was measured. Alleles complemented here to plus chromosomal strand.	risperidone
1183699417	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5	PMID:23609392	CYP2D6	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.	yes	= 0.001	42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	Poor metabolizers (PM) either had the *4/*4 genotype (n=1) or were taking strong CYP2D6 inhibitors paroxetine (n=1) or levomepromazine (n=1). These patients had a 3.3-fold higher dose-corrected risperidone level, a 2.7-fold higher dose-corrected 9-hydroxyrisperidone level, and a 9.1-fold higher risperidone/9-hydroxy-risperidone ratio, as compared to patients with the intermediate (*1/*3, *1/*4, *1/*5, *4/*XN), extensive (*1/*1) or ultrarapid metabolizer (*1/*XN, *XN/*XN) phenotypes. No significant associations were seen when considering active moiety.	risperidone
1448266503	rs2032582	PMID:26129906	ABCB1	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele A.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
769261698	rs3813929	PMID:21121776	HTR2C	Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.	yes	= 0.006			Multiple groups, Mostly European samples	Other	false	In this meta-analysis, statistical significance was gained when looking at mostly European populations. This gene is on the X chromosome, males on have one copy.	amisulpride; clozapine; haloperidol; iloperidone; olanzapine; quetiapine; risperidone; ziprasidone
1183915979	CYP2D6*3; CYP2D6*4	PMID:22775532	CYP2D6	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is not associated with differences in treatment response or scores on the various subscales of the PANSS when treated with haloperidol or risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.	no	> 0.05	35		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05). 22 EM and 3 PM. AmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	haloperidol; risperidone
1449000705	rs6277	PMCID:PMC4736591	DRD2	Genotype GG is associated with increased likelihood of Insulin Resistance when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AA + AG.	not stated	= 0.053	22	98	Multiple groups, Brazilian mixed	Toxicity	true	Results are described for Presence of allele T vs Absence of allele T. Alleles were complemented.	risperidone
1447675159	rs3813034	PMID:26556226	SLC6A4	Genotype AA is associated with increased likelihood of Weight gain when treated with risperidone in people with Schizophrenia as compared to genotypes AC + CC.	yes	= 0.001	215		East Asian	Other	false	Three ther SNPs in SLC6A4 were also associated with weight gain in this study but the alleles were not specified so could not be annotated (rs1042173, rs4325622, rs9303628).	risperidone
1183960050	CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:22592207	CYP2D6	CYP2D6 *4/*4 + *4/*5 + *4/*6 (assigned as poor metabolizer phenotype) is associated with decreased reduction in psychotic symptoms when treated with risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.	yes	= 0.01712	35		Unknown	Efficacy	false	Due to low number IM and EM patients were pooled. No explanation of how metabilzers were assigned, no diplotypes reported. The following alleles were presented *1, *2, *4, *5, *6, *9, *10, *27, *33, *41. One UM patient was found but exlcluded from analysis. Co-medication with other antipsychotics was allowed. symptom reduction was measured as % reduction in PANSS score.	risperidone
655387253	rs7799039	PMCID:PMC2919234	LEP	Allele A is associated with increased likelihood of Weight gain when treated with risperidone in children as compared to genotype GG.	yes	= 0.03	74		Multiple groups	Toxicity	true		risperidone
1184748530	CYP2D6 poor metabolizer	PMID:25042870	CYP2D6	CYP2D6 poor metabolizer are associated with decreased clearance of risperidone in healthy individuals.	yes	< 0.011	70		Multiple groups, 67 Caucasian, 3 Hispanic	Metabolism/PK	false	Poor CYP2D6 metabolizers showed higher risperidone maximum plasma concentrations (Cmax; p=0.011), area under the curve (AUC; p<0.0001) and half-life time (t1/2; p<0.0001) as well as decreased clearance (Cl; p<0.0001), as compared to those who were intermediate, extensive or ultrarapid metabolizers. Additionally, poor CYP2D6 metabolizers showed decreased Cmax and AUC, and increased t1/2 of 9-hydroxyrisperidone, as compared to intermediate, extensive or ultrarapid metabolizers (all p<0.0001). These p-values come from multivariate analysis. 9-hydroxyrisperidone is formed from the metabolism of risperidone by CYP2D6.	risperidone
1448266530	rs1045642	PMID:26129906	ABCB1	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
655387233	rs6311	PMID:19997080	HTR2A	Genotypes CT + TT are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype CC.	yes	= 0.019	45		Multiple groups, Portugal: 44 white, 1 african	Efficacy	true	as measured by decrease in ATEC score. Alleles complemented to plus chromosomal strand.	risperidone
1448993578	CYP2D6 poor metabolizer genotype	PMID:25868121	CYP2D6	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of risperidone in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	yes	< 0.0001	389		European	Metabolism/PK	false		risperidone
655387241	rs3813928	PMID:19997080	HTR2C	Allele A is associated with decreased response to risperidone in children with Autistic Disorder as compared to genotype GG.	yes	= 0.035	45		Multiple groups, Portugal: 44 white, 1 african	Efficacy	true	HTR2C is on the X chromosome and this variant described as rs3813928 (c.-995G>A). Males with A genotype plus females with AA/AG genotype had 4.1% higher ATEC (ie. less response) than males with G genotype or females with GG genotype.	risperidone
1448266539	rs1128503	PMID:26129906	ABCB1	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.	no	= 0.02	150		Multiple groups, 81% Caucasian	Metabolism/PK	false		risperidone
1183699447	rs4646437	PMID:23609392	CYP3A4	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.	no		42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No association was found between this SNP and risperidone, 9-hydroxy-risperidone or active moiety plasma levels, risperidone/9-hydroxy-risperidone ratio, or dose requirements (data not shown). Please note alleles have been complemented to the plus chromosomal strand.	risperidone
1448998695	rs3813929	PMID:20680028	HTR2C	Allele T is not associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no		186		European	Toxicity	false	Note: this is an x-linked gene so male subjects have only one copy of the allele (T or C) whereas female subjects can be TT, CT or CC.	antipsychotics; aripiprazole; clozapine; olanzapine; quetiapine; risperidone
1446898502	rs7799039	PMCID:PMC3693401	LEP	Allele G is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele A.	yes	= 1.29E-9	181		Unknown	Other	true	"Age corrected BMI increases over the 8 wk period after initiating risperidone were as follows: GG= 1.37 and AG=1.43, AA=1.07.  This, is considered a ""risk allele"" for risperidone associated weight-gain. The authors calculated a risk score based on the number of risk alleles a patient carried. Two other SNPs (rs1049353 G and rs806378 T) were considered risk alleles. The authors estimated risk with allele dosage (0,1,2, or 3 risk alleles) and predicted weight gain in the overall sample."	risperidone
1446898620	rs10244329	PMCID:PMC3693401	LEP	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.	no	= 9.6E-3	181		Multiple groups, 70% Caucasian	Other	true	The SNP was not significant after Bonferroni correction for 19 tests.	risperidone
1448998876	rs3813928	PMID:20504252	HTR2C	Genotype GG is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + AG.	yes	= 0.038	62	66	European	Toxicity	false	Groups compared were GG females plus G males vs AG females + AA females + A males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1450928121	rs362267	PMCID:PMC5538123	HTT	Allele T is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	no	> 0.05	288		East Asian	Efficacy	false	The T allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
981238777	rs3738883	PMCID:PMC3518380	TMEFF2	Allele G is associated with response to risperidone in people with Schizophrenia.	yes	= 4.11E-4	97		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: reported allele was C, this has been complemented to the plus chromosomal strand. It was unclear whether the allele was associated with an increased or decreased response to drug.	risperidone
1183620362	rs2032582	PMCID:PMC1884506	ABCB1	Allele C is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.	no		85		East Asian	Metabolism/PK	false	No association was seen between this SNP and metabolism of risperidone.	risperidone
1450928113	rs6280	PMCID:PMC5538123	DRD3	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.	no	> 0.05	288		East Asian	Efficacy	false	The C allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
1448998866	rs498207	PMID:20504252	HTR2C	Genotype AA is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.	yes	= 0.0196	62	66	European	Toxicity	false	Groups compared were AA females plus A males vs AG females + GG females + G males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1446898605	rs489693	PMCID:PMC3693401	MC4R	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.	no	= 0.03	181		Multiple groups, 70% Caucasian	Other	true	The SNP was not significant after Bonferroni correction for 19 tests.	risperidone
1183620382	rs1045642	PMCID:PMC1884506	ABCB1	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.	no		85		East Asian	Metabolism/PK	false	No association was seen between this SNP and metabolism of risperidone.	risperidone
981238767	rs1315115	PMCID:PMC3518380	NPAS3	Allele G is associated with response to risperidone in people with Schizophrenia.	yes	= 3.04E-4	97		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant.  Please note: the allele was reported as C (though this gene is found on the plus chromosomal strand). It was unclear whether the allele was associated with an increased or decreased response to drug.	risperidone
1450928104	rs10012	PMCID:PMC5538123	CYP1B1	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	no	> 0.05	288		East Asian	Efficacy	false	The C allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
981238760	rs1869295	PMCID:PMC3518380	AGAP1	Allele C is associated with response to risperidone in people with Schizophrenia.	yes	= 2.05E-4	97		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	risperidone
1448997834	rs3813929	PMID:25152019	HTR2C	Allele C is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele T.	no	= 0.34	843		Multiple groups, Mostly Caucasian, ranging from 88% white to 100% white cases, one study Korean Asian, one unknown,	Toxicity	false	Article has typo in rs number and lists rs3813829 as equivalent to -759C>T. Corrected here to the appropriate rs number. This gene is on the X chromosome and analysis was done for presence of T allele vs absence of T allele.	clozapine; olanzapine; risperidone
981475608	rs10042486	PMID:22120873	HTR1A	Genotype TT is associated with increased response to amisulpride, antipsychotics, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 1.0E-6	221		East Asian	Efficacy	false	Response was measured by difference in PANSS scores between admission and discharge. Subjects with the TT genotype were more likely to improve on the PANSS total, positive and negative scores as compared to the CC + CT genotypes. Percentages of study participants taking each drug are as follow: risperidone (34%), olanzapine (24%), quetiapine (6%), amisulpiride (15%), and other antipsychotics (4%).	amisulpride; antipsychotics; olanzapine; quetiapine; risperidone
1448530382	CYP2D6*1; CYP2D6*2; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*41	PMID:26944100	CYP2D6	CYP2D6 *5/*10 + *4/*10 + *10/*10 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .	yes	< 0.001	79		East Asian	Metabolism/PK	true	Genotyped with Luminex xTAG CYP2D6 Kit v3, which can identify *1, *2, *35,*9, *10, *17, *29, *41, *3, * 4, *5, *6, *7, *8, *11, *15, and duplications. The plasma concentration of risperidone in subjects with IM (n=33) (1.85 ng/ml) was significantly higher than EM (n=46) (0.43 ng/ml, P < 0.0001) phenotype. The plasma concentration of risperidone/9-hydroxyrisperidone ratio in subjects with IM (0.20) phenotype was significantly higher than EM (0.05, P < 0.0001).	risperidone
1450928098	rs1056827	PMCID:PMC5538123	CYP1B1	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	no	> 0.05	142		East Asian	Efficacy	false	The A allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
1448998855	rs3813929	PMID:20415561	HTR2C	Genotype TT is not associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CC + CT.	no	= 0.062	82		East Asian	Efficacy	false	This was not significant in male or female patients. The HTR2C is x-linked and males have only one copy, the authors analyzed male and female samples separately.	risperidone
1446898598	rs8093815	PMCID:PMC3693401		Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele G.	no	= 0.07	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1448998848	rs9698290	PMID:20415561	HTR2C	Genotype TT is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CC + CT.	yes	= 0.019	82		East Asian	Efficacy	false	This was not significant in male patients. The HTR2C is x-linked and males have only one copy, the authors analyzed male and female samples separately.	risperidone
981238754	rs874295	PMCID:PMC3518380	LRP1B	Allele G is associated with response to risperidone in people with Schizophrenia.	yes	= 1.85E-4	97		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: reported allele was C, this has been complemented to the plus chromosomal strand. It was unclear whether the allele was associated with an increased or decreased response to drug.	risperidone
1449005504	rs2231142	PMID:28719598	ABCG2	Genotypes GT + TT is associated with increased risk of adverse events when treated with risperidone in children as compared to genotype GG.	yes	= 0.004	64		European	Toxicity	true	"Alleles complemented to plus chromosomal strand. Types of adverse events were classified as ""metabolism and nutrition disorders"""	risperidone
981238748	rs9713	PMCID:PMC3518380	PSMD14	Allele A is associated with response to risperidone in people with Schizophrenia.	yes	= 4.99E-5	97		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	risperidone
1450823641	rs2514218	PMCID:PMC4601717	DRD2	Genotype CC is not associated with severity of Psychomotor Agitation due to risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.	no	> 0.05	51		Multiple groups, Asian, African American, Hispanic, Caucasian and Other ethnicities.	Toxicity	true	No significant association between this variant and severity of akathisia over 12 weeks of treatment.	risperidone
1448998908	rs10490624	PMID:20504252	INSIG2	Genotype TT is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotype CT.	no	= 0.0196	62	66	European	Toxicity	false	No CC homozygotes in sample set.	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1446898591	rs11872992	PMCID:PMC3693401	MC4R	Allele G is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele A.	no	= 0.03	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1450928092	rs6706232	PMCID:PMC5538123	UGT1A3	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	no	> 0.05	288		East Asian	Efficacy	false	The A allele was initially significantly more frequent in patients designated as responders to risperidone (i.e. >50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing.	risperidone
1445296525	rs5326	PMID:25179995	DRD1	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no		185		East Asian	Efficacy	false	No significant differences in genotype or allele frequencies were observed between responders and non-responders. Patients were either part of the Shanghai (n=97) or Henan (n=88) cohorts. Response based on a cut-off of 50% in terms of corrected percent change of Positive and Negative Syndrome Scale (PANSS). Patients treated with risperidone monotherapy for 4 weeks.	risperidone
1448998900	rs17587100	PMID:20504252	INSIG2	Genotype AA is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1450823635	rs2514218	PMCID:PMC4601717	DRD2	Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.	yes	= 0.044	100		Multiple groups, Asian, African American, Hispanic, Caucasian and Other ethnicities.	Efficacy	true	Patients with the CC genotype had a greater reduction in symptoms over 12 weeks of treatment with either aripiprazole or risperidone.	aripiprazole; risperidone
1446898582	rs8087522	PMCID:PMC3693401	MC4R	Allele G is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele A.	no	= 0.06	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1451151829	rs6313	PMID:32462699	HTR2A	Genotypes AA + AG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.	yes	= 0.05	121		European	Efficacy	false	Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly increased improvement in negative symptoms was noted across the genotypes GG<AG<AA.	risperidone
1184168762	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:20031235	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	yes	= 0.05	147		European	Efficacy	false	The L/S (Long/Short) genotype was associated with better negative symptom response to antipsychotic treatment, especially olanzapine, than either of the homozygous genotypes were.  This article described the alleles only as L and S- not clear on exact sequence.  Association was significant for the SANS but not the BPRS or SAPS. 6 week response was assessed.	antipsychotics; haloperidol; olanzapine; risperidone
655387327	rs1128503	PMID:19997080	ABCB1	Genotypes AA + AG are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype GG.	yes	= 0.05	45		"Multiple groups, Portugal: 44 white, 1 African "	Efficacy	true	Alleles complemented to plus chromosomal strand. Patients with the ABCB1 c.1236C>T,  TT or CT genotypes had 4.7% lower ATEC scores than CC homozygotes	risperidone
769261685	rs518147	PMID:21121776	HTR2C	Allele G is associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine and risperidone in people with Schizophrenia as compared to allele C.	yes	= 0.019	205		Multiple groups	Other	false	A significant association was not found with genotypes groups but when women were analyzed separately there is a borderline p value. This gene is on the X chromosome and males have only one copy, so genotypes are G and C. Of the CC women (n=6) zero were in the weight gain group, 7 of 27 CG women gained weight whereas 14 of 29 GG women gained weight.	clozapine; haloperidol; olanzapine; risperidone
982015800	rs2020917	PMID:22935916	COMT	Allele C is associated with decreased response to risperidone in people with Schizophrenia.	yes	= 0.038	130		East Asian	Efficacy	false	"When combined with the C allele in rs9606186 and the C allele in rs933271. Patients with the haplotype C-C-C across these three SNPs have poorer response to risperidone. ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders""."	risperidone
1445296532	rs4867798	PMID:25179995	DRD1	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no		185		East Asian	Efficacy	false	No significant differences in genotype or allele frequencies were observed between responders and non-responders. Patients were either part of the Shanghai (n=97) or Henan (n=88) cohorts. Response based on a cut-off of 50% in terms of corrected percent change of Positive and Negative Syndrome Scale (PANSS). Patients treated with risperidone monotherapy for 4 weeks.	risperidone
1448998892	rs7799039	PMID:20504252	LEP	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + AG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1447682043	CYP2D6 poor metabolizer	PMID:26514968	CYP2D6	CYP2D6 poor metabolizer is associated with increased concentrations of risperidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	yes	= 0.009	15		Unknown	Metabolism/PK	false	The authors evaluated the pharmacokinetics of multiple antipsychotics, including risperidone, in 82 individuals, 20 of whom were treated with risperidone. The authors grouped patients according to CYP2D6 genotype into 6 categories of metabolizer phenotypes: poor metabolizers (*4/*4, *3/*4, *4/*6, *4/*4), intermediate metabolizers (*4/*41, *10/*10), extensive metabolizer- slow (*1/*3, *1/*4, *1/*5, *2/*3, *2/*4, *2/*5, *4/*35, *1/*10, *1/*41,*2/*41), extensive metabolizer-fast (*1/*1, *1/*2,*1/*35, *2/*2, *35/*35), and ultra rapid metabolizer (*1/*2xN, *1/*35xN, *2/*2xN, *2/*35xN).	risperidone
1448997871	rs7799039	PMID:18515891	LEP	Genotypes AG + GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with Schizophrenia as compared to genotype AA.	yes	= 0.032	120		Unknown	Toxicity	false	Variant referred to in paper as -2548A/G	clozapine; olanzapine; risperidone
1184754478	CYP2D6 poor metabolizers	PMID:24643635	CYP2D6	CYP2D6 poor metabolizers are associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer and ultra-metabolizer.	not stated					Metabolism/PK	false	Receiver under the operator curve (ROC) method and area under curve (AUC) were calculated and then used to predict metabolic ratio (risperidine/9-OH-risperidone) for individual CYP2D6 genotypes. To evaluate the proposed cutoff of metabolic ratio of >1 to predict whether an individual is a poor metabolizer the sensitivity (75%) specificity (95%), positive predictive value (60%), and negative predictive value (97%) were calculated.	risperidone
1447679482	rs723672	PMID:26049408	CACNA1C	Allele C is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.16	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
981859123	rs9606186	PMID:22935916	COMT	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	yes	= 0.02	45		East Asian	Efficacy	false	"The GG genotype group had a higher percentage of ""responders"" compared to the CG and CC genotype groups. ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders"". Significant results were seen for the entire study population and the male subgroup (n = 45). No significant results were seen for the female subgroup (n = 85)."	risperidone
1183620411	CYP2D6*1; CYP2D6*4	PMID:15260906	CYP2D6	CYP2D6 *4 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	yes	= 0.05	35		European	Metabolism/PK	false	Patients carrying the *4 allele showed greater risperidone concentrations, active moiety (risperidone+9-OH-risperidone) concentrations, and risperidone/9-OH-risperidone ratios as compared to patients with the *1/*1 genotype. Patients carrying the *4 allele also showed longer QTc intervals as compared to patients with the *1/*1 genotype, though this was not related to risperidone or 9-OH-risperidone plasma concentrations. This suggests that a different metabolite may be responsible for this effect.	risperidone
981859133	rs4680	PMID:22935916	COMT	Allele A is not associated with response to risperidone in people with Schizophrenia.	no	= 0.88	130		East Asian	Efficacy	false	"No significant association was seen between any rs4680 allele or genotype and the number of ""responders"". ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders""."	risperidone
1448998884	rs3813929	PMID:20504252	HTR2C	Genotype CC is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CT + TT.	yes	= 0.04	62	66	European	Toxicity	false	Groups compared were CC females plus C males vs CT females + TT females + T males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1184754471	CYP2D6 ultrarapid metabolizer	PMID:24643635	CYP2D6	CYP2D6 ultrarapid metabolizer is associated with increased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 poor metabolizers.	not stated					Metabolism/PK	false	Receiver under the operator curve (ROC) method and area under curve (AUC) were calculated and then used to predict metabolic ratio (risperidine/9-OH-risperidone) for individual CYP2D6 genotypes. To evaluate the proposed cutoff of metabolic ratio of <0.01 to predict whether an individual is an ultra rapid metabolizers the sensitivity (80%) specificity (77%), positive predictive value (18%), and negative predictive value (98%) were calculated.	risperidone
1447987701	rs1415744	PMID:27092952	EPM2A	Allele C is associated with increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone or trifluoperazine in people with Schizophrenia as compared to allele T.	yes	= 0.02	573		East Asian	Efficacy	false	Symptom improvement measured by PANSS score (Positive and Negative Symptom Scale) after 20-40 days of treatment. The CC genotype was associated with an improved response compared to CT, which was also associated with an improved response compared to TT. The CG haplotype of rs1415744 and rs702304 was associated with improvement on the negative symptom scale (p=0.02).	chlorpromazine; clozapine; haloperidol; olanzapine; quetiapine; risperidone; trifluoperazine
1451440440	rs2740574	PMID:23609392	CYP3A4	Allele C is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele T.	no		42		Multiple groups, Caucasian, African, Unknown	Metabolism/PK	false	No association was found between this * allele and risperidone, 9-hydroxy-risperidone or active moiety plasma levels, risperidone/9-hydroxy-risperidone ratio, or dose requirements (data not shown). Typo in methods of paper wrongly assigns rs number for *1B. Mapped *1B to rs2740574 C and *1A to rs2740574 T based on PharmVAR consolidation of core alleles.	risperidone
1446898560	rs1121980	PMCID:PMC3693401	FTO	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele G.	no	= 0.78	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1447679991	rs2283271	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.07	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1445296539	rs4532	PMID:25179995	DRD1	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no		185		East Asian	Efficacy	false	No significant differences in genotype or allele frequencies were observed between responders and non-responders. Patients were either part of the Shanghai (n=97) or Henan (n=88) cohorts. Response based on a cut-off of 50% in terms of corrected percent change of Positive and Negative Syndrome Scale (PANSS). Patients treated with risperidone monotherapy for 4 weeks.	risperidone
1183621939	CYP2D6*1; CYP2D6*10	PMID:15729081	CYP2D6	CYP2D6 *10 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	no		39		East Asian	Metabolism/PK	false	Metabolic ratio, clinical outcome, and concentrations of risperidone, 9-OH-risperidone and active moiety (risperidone + 9-OH-risperidone) were not associated with CYP2D6 genotype.	risperidone
769246747	rs2228622	PMID:19884611	SLC1A1	Allele A is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.	yes	= 0.04	40	54	East Asian	Toxicity	false	"In this pharmacogenetic case-control study of outpatient schizophrenic clinic, trends of association were observed in rs2228622 and rs3780412 (nominal P=.01; adjusted permutation P=.07) for the dominant model that was the inheritance model that best fit our data. In the haplotype-based analysis, the A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with AAP-induced OC symptoms; this association
withstood multiple test correction (nominal
P=.01; adjusted permutation P=.04; odds ratio,3.955; 95% confidence interval, 1.366-11.452, for dominant model)."	clozapine; olanzapine; risperidone
982015818	rs9606186	PMID:22935916	COMT	Allele C is associated with decreased response to risperidone in people with Schizophrenia.	yes	= 0.038	130		East Asian	Efficacy	false	"When combined with the C allele in rs2020917 and the C allele in rs933271. Patients with the haplotype C-C-C across these three SNPs have poorer response to risperidone. ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders""."	risperidone
1448530835	CYP2D6*1; CYP2D6*4	PMID:15669884	CYP2D6	CYP2D6 *4/*4 is associated with increased risk of adverse events when treated with risperidone as compared to CYP2D6 *1/*1.	yes	< 0.05			Multiple groups	Toxicity	false	Poor metabolizer phenotype increased the odds of having moderate adverse drug reactions (OR 3.4 CI = 1.5 to 8.0; multivariant analysis) compared to normal metabolizers. *2, *3, *4, *5, *6, *8, *9, *10, *11, *14, *15, *17, *18, *19,*20, *25, *26, *29, *30, *31, *35, *36, *37, *40, *41, *43,and *52 were genotyped and PMs are carriers of two no function alleles, while NMs having one or two functional alleles.	risperidone
769246751	rs3780413	PMID:19884611	SLC1A1	Allele G is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.	yes	= 0.04	40	54	East Asian	Toxicity	false	"In this pharmacogenetic case-control study of outpatient schizophrenic clinic, trends of association were observed in rs2228622 and rs3780412 (nominal P=.01; adjusted permutation P=.07) for the dominant model that was the inheritance model that best fit our data. In the haplotype-based analysis, the A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with AAP-induced OC symptoms; this association
withstood multiple test correction (nominal
P=.01; adjusted permutation P=.04; odds ratio,3.955; 95% confidence interval, 1.366-11.452, for dominant model)."	clozapine; olanzapine; risperidone
1448998811	rs3813928	PMID:17016522	HTR2C	Allele A is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no		138		European	Toxicity	false	Authors state this SNP only significant as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C/rs3813928 G, rs518147 C and rs1414334 C. This SNP was in linkage with rs3813929 (-759 C/T), with T and A found together. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone
1183620420	CYP2C9*1; CYP2C9*2	PMID:15260906	CYP2C9	CYP2C9 *2 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2C9 *1.	no	= 0.05	35		European	Metabolism/PK	false	Variants (*2 or *3) in the CYP2C9 gene were not shown to have any effect on metabolism of risperidone or length of QTc.	risperidone
1446898677	rs324420	PMCID:PMC3693401	FAAH	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.	no	= 0.19	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1448998293	rs3813929	PMID:18515891	HTR2C	Allele C is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.97	120		Unknown	Toxicity	false	Variant is described as -759C/T. As the 5-HT2C receptor gene is linked to the X chromosome, male participants were genotyped hemizygotes C or T with 15 of 84 (18%) having the T allele. Among female participants, 15 of 45 (33%) were heterozygotic; none were homozygous for the T allele.	clozapine; olanzapine; risperidone
982015810	rs933271	PMID:22935916	COMT	Allele C is associated with decreased response to risperidone in people with Schizophrenia.	yes	= 0.038	130		East Asian	Efficacy	false	"When combined with the C allele in rs9606186 and the C allele in rs2020917. Patients with the haplotype C-C-C across these three SNPs have poorer response to risperidone. ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders""."	risperidone
1446895600	rs2299214	PMID:25209194	GRM3	Genotypes CC + CT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotype TT.	yes	= 0.039	145		Central/South Asian	Efficacy	false	"Only in patients who were in the ""high severity group"" based on baseline severity score, using clinical global impressions (CGI) score. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale. Those with the CC or CT genotype were more prevalent in the IR group. Note that this association did not withstand correction for multiple testing."	risperidone
1448604057	rs12535512	PMCID:PMC5563830	ABCB1	Genotypes CC + CT are not associated with response to risperidone in people with Schizophrenia as compared to genotype TT.	yes	= 0.144	171		East Asian	Efficacy	false	Efficacy measured with reduction in PANSS total score reduced rate.	risperidone
981859157	rs4633	PMID:22935916	COMT	Allele C is not associated with response to risperidone in people with Schizophrenia.	no	= 0.94	130		East Asian	Efficacy	false	"No significant association was seen between any rs4633 allele or genotype and the number of ""responders"". ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders""."	risperidone
1448998799	rs3813929	PMID:17016522	HTR2C	Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	no		138		European	Toxicity	false	Authors state this SNP only significant as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C, rs518147 C and rs1414334 C. This SNP was in linkage with rs3813928 (-997 G/A), with T and A found together. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone
1446898670	rs806368	PMCID:PMC3693401	CNR1	Allele C is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.	no	= 0.26	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1448604036	rs2032582	PMCID:PMC5563830	ABCB1	Genotype CC is not associated with response to risperidone in people with Schizophrenia as compared to genotype AA.	no	= 0.998	171		East Asian	Efficacy	false	Alleles given as reverse strand G, A and T. Efficacy measured with reduction in PANSS total score reduced rate. No difference found in PANSS reduction in any genotype.	risperidone
1183620440	CYP2C9*1; CYP2C9*3	PMID:15260906	CYP2C9	CYP2C9 *3 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2C9 *1.	no	= 0.05	35		European	Metabolism/PK	false	Variants (*2 or *3) in the CYP2C9 gene were not shown to have any effect on metabolism of risperidone or length of QTc.	risperidone
655387845	rs167771	PMID:19506579	DRD3	Allele G is associated with increased risk of extrapyramidal symptoms when treated with risperidone in people with Bipolar Disorder or Schizophrenia as compared to allele A.	yes	= 1.3E-4	81	189	European	Toxicity	false		risperidone
1446898663	rs806377	PMCID:PMC3693401	CNR1	Allele C is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.	no	= 0.17	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1448998790	rs1414334	PMID:17016522	HTR2C	Allele C is associated with increased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	yes		138		European	Toxicity	false	Authors state this SNP was significant alone and as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C, rs518147 C and rs1414334 C. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone
1446898656	rs2071045	PMCID:PMC3693401	LEP	Allele C is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.	no	= 0.19	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1448604042	rs1128503	PMCID:PMC5563830	ABCB1	Genotypes AG + GG are not associated with response to risperidone in people with Schizophrenia as compared to genotype AA.	yes	= 0.783	171		East Asian	Efficacy	false	Alleles given as reverse strand C and T. Efficacy measured with reduction in PANSS total score reduced rate.	risperidone
981501278	rs3787430	PMID:21652606	HRH3	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 0.01	129		East Asian	Efficacy	false	Response was measured by reduction in Brief Psychiatric Rating Scale (BPRS) scores after 4 and 8 weeks of treatment. The statistical analysis comparing genotypes with score reductions was completed using ANOVA, so the p-value quoted is for association between all three genotypes and score reduction. It is therefore unclear which set of two genotypes have significantly different score reductions.	risperidone
1183904079	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:24232129	CYP2D6	CYP2D6 intermediate metabolizers is not associated with serum concentration of 9-hydroxyrisperidone or sum of risperidone and 9-hydroxyrisperidone when treated with risperidone as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6.	no		190		European	Metabolism/PK	false	Note: the association is reported for carriers of a def/red and red/red alleles (see below) compared to patients with *1/def genotypes. The specific diplotype of the patients is not given (see below). def: *3 (2549delA), *4 (1846 G>A), *5 (gene deletion), *6 (1707delT), red:*9 (2615_2617delAAG), *10 (100C>T), and *41 (2988 G>A). In the total cohort for both treatments 179 patients were carriers of CYP2D6*1/*1 genotype, 65 patients were carriers of CYP2D6*1/red genotype, 129 patients were carriers of CYP2D6*1/def genotype, 15 patients were carriers of CYP2D6*red/red genotype, 27 patients were carriers of CYP2D6def/red genotype, and 41 patients were carriers of CYP2D6def/def genotype.	risperidone
1449731979	rs1045642	PMID:29723928	ABCB1	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.	yes	< 0.05	70		Unknown	Metabolism/PK	false	Please note that alleles have been complemented to the positive strand. GG genotype at rs1045642 was significantly associated with increased AUC, Cmax, half-life and Cl/F of risperidone. The half-life of the metabolite 9-OH-risperidone was also significantly increased, however this significance was lost following multivariate analysis.	paliperidone; risperidone
1448997822	rs518147	PMID:25152019	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	yes	= 0.05	422		Multiple groups, Two studies that were mostly Caucasian, ranging from 88% white to >95% white cases and one in Korean Asian cases	Toxicity	false	"Authors note significance as ""marginal"". This gene is on the X chromosome and analysis was done for presence of C allele vs absence of C allele."	clozapine; olanzapine; risperidone
1446898649	rs12706832	PMCID:PMC3693401	LEP	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele G.	no	= 0.09	181		Multiple groups, 70% Caucasian	Other	true		risperidone
1183619945	CYP2D6*1; CYP2D6*10	PMID:11791898	CYP2D6	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	yes	= 0.004	82		East Asian	Metabolism/PK	false	A gene-dose effect was observed in that with increasing numbers of *10 alleles, lower metabolism (higher concentration/dose and metabolic ratios) of risperidone was seen.	risperidone
981501287	rs3787429	PMID:21652606	HRH3	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 0.013	129		East Asian	Efficacy	false	Response was measured by reduction in Brief Psychiatric Rating Scale (BPRS) scores after 4 and 8 weeks of treatment. The statistical analysis comparing genotypes with score reductions was completed using ANOVA, so the p-value quoted is for association between all three genotypes and score reduction. It is therefore unclear which set of two genotypes have significantly different score reductions. The difference in reduction between genotypes was not significantly different after 8 weeks of treatment.	risperidone
608431018	rs6313	PMID:19494443	HTR2A	Allele A is associated with increased risk of treatment-resistance when treated with olanzapine and risperidone in people with Alzheimer Disease as compared to allele G.	not stated		80		European	Efficacy	false		olanzapine; risperidone
1448998839	rs1023574	PMID:20415561	HTR2C	Genotype CC is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CG + GG.	yes	= 0.016	82		East Asian	Efficacy	false	This was not significant in male patients. The HTR2C is x-linked and males have only one copy, the authors analyzed male and female samples separately.	risperidone
1447945120	rs3813929	PMCID:PMC4736591	HTR2C	Genotypes CC + CT are associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotype TT.	not stated	= 0.054	120		Multiple groups, Brazilian mixed	Toxicity	true	"Alleles given as G and A in table, from frequency looks like G should be C and A should be T. This gene is on the X chromosome and analysis was for ""Presence of allele G"" i.e. CC and CT females and C males vs ""Absence of allele G"" ie. TT females and T males in obese/overweight group and not obese/overweight group."	risperidone
1448997808	rs1414334	PMID:25152019	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	yes	= 0.0004	462		Multiple groups, Mostly Caucasian, ranging from 88% white to >95% white cases	Toxicity	false	This gene is on the X chromosome and analysis was done for presence of C allele vs absence of C allele.	clozapine; olanzapine; risperidone
1448640439	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	PMID:28389049	CYP2D6	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with decreased dose of risperidone in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer genotypes.	yes	= 0.014	70		Multiple groups	Dosage	false	Significant differences in the mean daily dosage of risperidone was observed between CYP2D6 poor metabolizers (PM; 4.0+/-2.3 mg/day), intermediate metabolizers (IM; 4.56+/-2.44), extensive metabolizers (EM; 6.22+/-4.0) and ultrarapid metabolizers (UM; 10.2+/-4.91). Post-hoc comparisons identified significant differences between UMs and PMs (p=0.019) and UMs and IMs (p=0.009). No association was seen for the concentration/dose ratio or when considering concentrations of the metabolite 9-hydroxyrisperidone. 5 PMs, 25 IMs, 35 EMs and 5 UMs were present in the cohort.	risperidone
982022009	rs6295	PMID:18308786	HTR1A	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	yes	= 0.038	125		East Asian	Dosage,Efficacy	false	Paper reports that CC subjects showed substantial improvement compared to CC + CG subjects.  This is ambiguous with regards to strand.  The HTR1A gene is on the negative chromosomal strand, so I complemented the reported alleles.	risperidone
1448998827	rs518147	PMID:20415561	HTR2C	Genotype CC is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CG + GG.	yes	= 0.011	82		East Asian	Efficacy	false	This was not significant in male patients. The HTR2C is x-linked and males have only one copy, the authors analyzed male and female samples separately.	risperidone
982022015	rs5443	PMID:18308786	GNB3	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	no	> 0.05	125		East Asian	Dosage,Efficacy	false		risperidone
769246755	rs3780412	PMID:19884611	SLC1A1	Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.	yes	= 0.04	40	54	East Asian	Toxicity	false	In this pharmacogenetic case-control study of outpatient schizophrenic clinic, trends of association were observed in rs2228622 and rs3780412 (nominal P=.01; adjusted permutation P=.07) for the dominant model that was the inheritance model that best fit our data. In the haplotype-based analysis, the A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with AAP-induced OC symptoms; this association withstood multiple test correction (nominal P=.01; adjusted permutation P=.04; odds ratio,3.955; 95% confidence interval, 1.366-11.452, for dominant model).	clozapine; olanzapine; risperidone
699638857	rs2494732	PMID:18855532	AKT1	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 0.0201	120		East Asian	Efficacy	false		risperidone
699638861	rs3803300	PMID:18855532	AKT1	Genotype CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.	yes	= 0.0183	120		East Asian	Efficacy	false		risperidone
1448997283	rs680055	PMID:25150845	CYP3A43	Genotype CG is associated with increased response to antipsychotics, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to genotype CC.	yes	= 0.013	152		European	Efficacy	false	No GG homozygotes were observed. Approximately 50% of patients were receiving clozapine, the rest had other antipsychotics including risperidone (N = 25), olanzapine (N = 16), haloperidol (N = 7), amisulpride (N = 6), aripiprazole (N = 15), ziprasidone (N = 1), fluphenazine (N = 1) and quetiapine (N = 5)	antipsychotics; aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1448998819	rs518147	PMID:17016522	HTR2C	Allele C is associated with increased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no		138		European	Toxicity	false	Authors state this SNP only significant as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C/rs3813928 G, rs518147 C and rs1414334 C. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone